Mefloquine for preventing malaria in pregnant women by González, Raquel et al.
Cochrane Database of Systematic Reviews
Mefloquine for preventing malaria in pregnant women
(Review)
González R, Pons-Duran C, Piqueras M, Aponte JJ, ter Kuile FO, Menéndez C
González R, Pons-Duran C, Piqueras M, Aponte JJ, ter Kuile FO, Menéndez C.
Mefloquine for preventing malaria in pregnant women.
Cochrane Database of Systematic Reviews 2018, Issue 3. Art. No.: CD011444.
DOI: 10.1002/14651858.CD011444.pub2.
www.cochranelibrary.com
Mefloquine for preventing malaria in pregnant women (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
6BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
7OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
11RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
19ADDITIONAL SUMMARY OF FINDINGS . . . . . . . . . . . . . . . . . . . . . . . . . .
23DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
24AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
24ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
29CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
46DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 1 Clinical malaria episodes during
pregnancy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
Analysis 1.2. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 2 Maternal peripheral parasitaemia
at delivery. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
Analysis 1.3. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 3 Placental malaria. . . . . 49
Analysis 1.4. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 4 Mean haemoglobin at delivery. 50
Analysis 1.5. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 5 Maternal anaemia at delivery. 51
Analysis 1.6. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 6 Severe maternal anaemia at
delivery. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
Analysis 1.7. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 7 Cord blood parasitaemia. . 53
Analysis 1.8. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 8 Cord blood anaemia. . . . 53
Analysis 1.9. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 9 Mean birth weight. . . . 54
Analysis 1.10. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 10 Low birth weight. . . . 55
Analysis 1.11. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 11 Low birth weight by gravidity. 56
Analysis 1.12. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 12 Prematurity. . . . . . 57
Analysis 1.13. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 13 Malaria in first year of life. 57
Analysis 1.14. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 14 Hospital admissions in first year
of life. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
Analysis 1.15. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 15 SAEs during pregnancy. . 58
Analysis 1.16. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 16 Stillbirths and abortions. . 59
Analysis 1.17. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 17 Congenital malformations. 60
Analysis 1.18. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 18 Maternal mortality. . . 61
Analysis 1.19. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 19 Neonatal mortality. . . 62
Analysis 1.20. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 20 Infant mortality. . . . 62
Analysis 1.21. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 21 AEs: vomiting. . . . . 63
Analysis 1.22. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 22 AEs: fatigue/weakness. . 63
Analysis 1.23. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 23 AEs: dizziness. . . . . 64
Analysis 1.24. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 24 AEs: headache. . . . . 65
Analysis 2.1. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 1 Clinical malaria episodes
during pregnancy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
iMefloquine for preventing malaria in pregnant women (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 2.2. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 2 Maternal peripheral
parasitaemia at delivery (PCR). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
Analysis 2.3. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 3 Placental malaria (blood
smear). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
Analysis 2.4. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 4 Placental malaria (PCR). 67
Analysis 2.5. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 5 Mean haemoglobin at
delivery. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
Analysis 2.6. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 6 Maternal anaemia at delivery
(< 9.5 g/dL). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
Analysis 2.7. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 7 Maternal severe anaemia at
delivery. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
Analysis 2.8. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 8 Cord blood parasitaemia. 70
Analysis 2.9. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 9 Mean birth weight. . 70
Analysis 2.10. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 10 Low birth weight. . 71
Analysis 2.11. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 11 Prematurity. . . . 72
Analysis 2.12. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 12 SAEs during pregnancy. 72
Analysis 2.13. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 13 Spontaneous abortions
and stillbirths. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
Analysis 2.14. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 14 Congenital
malformations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
Analysis 2.15. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 15 Maternal mortality. 74
Analysis 2.16. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 16 Neonatal mortality. 75
Analysis 2.17. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 17 Mother-to-child
transmission HIV. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
Analysis 2.18. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 18 AEs: vomiting. . . 76
Analysis 2.19. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 19 AEs: fatigue/weakness. 77
Analysis 2.20. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 20 AEs: dizziness. . . 78
Analysis 2.21. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 21 AEs: headache. . . 78
Analysis 3.1. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 1 Maternal peripheral parasitaemia at delivery
(PCR). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
Analysis 3.2. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 2 Placental malaria (PCR). . . . . . . 80
Analysis 3.3. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 3 Placental malaria (blood smear). . . . . 80
Analysis 3.4. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 4 Mean haemoglobin at delivery. . . . . 81
Analysis 3.5. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 5 Maternal anaemia at delivery (< 9.5 g/dL). 81
Analysis 3.6. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 6 Mean birth weight. . . . . . . . . 82
Analysis 3.7. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 7 Low birth weight. . . . . . . . . . 82
Analysis 3.8. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 8 Prematurity. . . . . . . . . . . . 83
Analysis 3.9. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 9 SAEs during pregnancy. . . . . . . 83
Analysis 3.10. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 10 Stillbirths. . . . . . . . . . . 84
Analysis 3.11. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 11 Spontaneous abortions. . . . . . . 84
Analysis 3.12. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 12 Congenital malformations. . . . . . 85
Analysis 3.13. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 13 Maternal mortality. . . . . . . . 85
Analysis 3.14. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 14 Neonatal mortality. . . . . . . . 86
Analysis 3.15. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 15 Infant deaths after 7 days. . . . . . 86
Analysis 3.16. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 16 AEs: vomiting. . . . . . . . . . 87
Analysis 3.17. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 17 AEs: fatigue/weakness. . . . . . . 87
Analysis 3.18. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 18 AEs: dizziness. . . . . . . . . . 88
Analysis 3.19. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 19 AEs: headache. . . . . . . . . . 88
Analysis 4.1. Comparison 4 Mefloquine versus placebo, Outcome 1 Maternal peripheral parasitaemia during pregnancy. 89
Analysis 4.2. Comparison 4 Mefloquine versus placebo, Outcome 2 Placental malaria. . . . . . . . . . . . 89
Analysis 4.3. Comparison 4 Mefloquine versus placebo, Outcome 3 Mean birth weight. . . . . . . . . . . 90
Analysis 4.4. Comparison 4 Mefloquine versus placebo, Outcome 4 Low birth weight. . . . . . . . . . . . 90
Analysis 4.5. Comparison 4 Mefloquine versus placebo, Outcome 5 Prematurity. . . . . . . . . . . . . . 91
iiMefloquine for preventing malaria in pregnant women (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 4.6. Comparison 4 Mefloquine versus placebo, Outcome 6 Stillbirths. . . . . . . . . . . . . . 91
Analysis 4.7. Comparison 4 Mefloquine versus placebo, Outcome 7 Spontaneous abortions. . . . . . . . . . 92
Analysis 4.8. Comparison 4 Mefloquine versus placebo, Outcome 8 Congenital malformations. . . . . . . . . 92
Analysis 4.9. Comparison 4 Mefloquine versus placebo, Outcome 9 Maternal mortality. . . . . . . . . . . 93
Analysis 4.10. Comparison 4 Mefloquine versus placebo, Outcome 10 Infant mortality. . . . . . . . . . . 93
93APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
94CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
94DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
94SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
95DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
iiiMefloquine for preventing malaria in pregnant women (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
[Intervention Review]
Mefloquine for preventing malaria in pregnant women
Raquel González1, Clara Pons-Duran1 , Mireia Piqueras1 , John J Aponte1, Feiko O ter Kuile2, Clara Menéndez1
1ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain. 2Department of Clinical Sciences, Liverpool School of Tropical
Medicine, Liverpool, UK
Contact address: RaquelGonzález, ISGlobal,Hospital Clínic -Universitat deBarcelona, Barcelona, Spain. raquel.gonzalez@isglobal.org.
Editorial group: Cochrane Infectious Diseases Group.
Publication status and date: New, published in Issue 3, 2018.
Citation: GonzálezR, Pons-DuranC, PiquerasM,Aponte JJ, terKuile FO,MenéndezC.Mefloquine for preventingmalaria in pregnant
women. Cochrane Database of Systematic Reviews 2018, Issue 3. Art. No.: CD011444. DOI: 10.1002/14651858.CD011444.pub2.
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of
The Cochrane Collaboration. This is an open access article under the terms of the Creative Commons Attribution-Non-Commercial
Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used
for commercial purposes.
A B S T R A C T
Background
TheWorld Health Organization recommends intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine
for malaria for all women who live in moderate to high malaria transmission areas in Africa. However, parasite resistance to sulfadoxine-
pyrimethamine has been increasing steadily in some areas of the region. Moreover, HIV-infected women on cotrimoxazole prophylaxis
cannot receive sulfadoxine-pyrimethamine because of potential drug interactions. Thus, there is an urgent need to identify alternative
drugs for prevention of malaria in pregnancy. One such candidate is mefloquine.
Objectives
To assess the effects of mefloquine for preventing malaria in pregnant women, specifically, to evaluate:
• the efficacy, safety, and tolerability of mefloquine for preventing malaria in pregnant women; and
• the impact of HIV status, gravidity, and use of insecticide-treated nets on the effects of mefloquine.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register, the Cochrane Central Register of Controlled Trials (CEN-
TRAL) in the Cochrane Library, MEDLINE, Embase, Latin American Caribbean Health Sciences Literature (LILACS), the Malaria
in Pregnancy Library, and two trial registers up to 31 January 2018. In addition, we checked references and contacted study authors to
identify additional studies, unpublished data, confidential reports, and raw data from published trials.
Selection criteria
Randomized and quasi-randomized controlled trials comparing mefloquine IPT or mefloquine prophylaxis against placebo, no treat-
ment, or an alternative drug regimen.
Data collection and analysis
Two review authors independently screened all records identified by the search strategy, applied inclusion criteria, assessed risk of
bias, and extracted data. We contacted trial authors to ask for additional information when required. Dichotomous outcomes were
compared using risk ratios (RRs), count outcomes as incidence rate ratios (IRRs), and continuous outcomes using mean differences
(MDs). We have presented all measures of effect with 95% confidence intervals (CIs). We assessed the certainty of evidence using the
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GRADE approach for the following main outcomes of analysis: maternal peripheral parasitaemia at delivery, clinical malaria episodes
during pregnancy, placental malaria, maternal anaemia at delivery, low birth weight, spontaneous abortions and stillbirths, dizziness,
and vomiting.
Main results
Six trials conducted between 1987 and 2013 from Thailand (1), Benin (3), Gabon (1), Tanzania (1), Mozambique (2), and Kenya (1)
that included 8192 pregnant women met our inclusion criteria.
Two trials (with 6350 HIV-uninfected pregnant women) compared two IPTp doses of mefloquine with two IPTp doses of sulfadoxine-
pyrimethamine. Two other trials involving 1363 HIV-infected women compared three IPTp doses of mefloquine plus cotrimoxazole
with cotrimoxazole. One trial in 140 HIV-infected women compared three doses of IPTp-mefloquine with cotrimoxazole. Finally, one
trial enrolling 339 of unknown HIV status compared mefloquine prophylaxis with placebo.
Study participants included women of all gravidities and of all ages (four trials) or > 18 years (two trials). Gestational age at recruitment
was > 20 weeks (one trial), between 16 and 28 weeks (three trials), or ≤ 28 weeks (two trials). Two of the six trials blinded participants
and personnel, and only one had low risk of detection bias for safety outcomes.
When compared with sulfadoxine-pyrimethamine, IPTp-mefloquine results in a 35% reduction in maternal peripheral parasitaemia
at delivery (RR 0.65, 95% CI 0.48 to 0.86; 5455 participants, 2 studies; high-certainty evidence) but may have little or no effect on
placental malaria infections (RR 1.04, 95% CI 0.58 to 1.86; 4668 participants, 2 studies; low-certainty evidence). Mefloquine results
in little or no difference in the incidence of clinical malaria episodes during pregnancy (incidence rate ratio (IRR) 0.83, 95% CI 0.65
to 1.05, 2 studies; high-certainty evidence). Mefloquine decreased maternal anaemia at delivery (RR 0.84, 95% CI 0.76 to 0.94; 5469
participants, 2 studies; moderate-certainty evidence). Data show little or no difference in the proportions of low birth weight infants (RR
0.95, 95% CI 0.78 to 1.17; 5641 participants, 2 studies; high-certainty evidence) and in stillbirth and spontaneous abortion rates (RR
1.20, 95% CI 0.91 to 1.58; 6219 participants, 2 studies; I2 statistic = 0%; high-certainty evidence). IPTp-mefloquine increased drug-
related vomiting (RR 4.76, 95% CI 4.13 to 5.49; 6272 participants, 2 studies; high-certainty evidence) and dizziness (RR 4.21, 95%
CI 3.36 to 5.27; participants = 6272, 2 studies; high-certainty evidence).
When compared with cotrimoxazole, IPTp-mefloquine plus cotrimoxazole probably results in a 48% reduction in maternal peripheral
parasitaemia at delivery (RR 0.52, 95% CI 0.30 to 0.93; 989 participants, 2 studies; moderate-certainty evidence) and a 72% reduction
in placental malaria (RR 0.28, 95% CI 0.14 to 0.57; 977 participants, 2 studies; high-certainty evidence) but has little or no effect on the
incidence of clinical malaria episodes during pregnancy (IRR 0.76, 95% CI 0.33 to 1.76, 1 study; high-certainty evidence) and probably
no effect on maternal anaemia at delivery (RR 0.94, 95% CI 0.73 to 1.20; 1197 participants, 2 studies;moderate-certainty evidence), low
birth weight rates (RR 1.20, 95% CI 0.89 to 1.60; 1220 participants, 2 studies; moderate-certainty evidence), and rates of spontaneous
abortion and stillbirth (RR 1.12, 95% CI 0.42 to 2.98; 1347 participants, 2 studies; very low-certainty evidence). Mefloquine was
associated with higher risks of drug-related vomiting (RR 7.95, 95% CI 4.79 to 13.18; 1055 participants, one study; high-certainty
evidence) and dizziness (RR 3.94, 95% CI 2.85 to 5.46; 1055 participants, 1 study; high-certainty evidence).
Authors’ conclusions
Mefloquine was more efficacious than sulfadoxine-pyrimethamine in HIV-uninfected women or daily cotrimoxazole prophylaxis in
HIV-infected pregnant women for prevention of malaria infection and was associated with lower risk of maternal anaemia, no adverse
effects on pregnancy outcomes (such as stillbirths and abortions), and no effects on low birth weight and prematurity. However, the high
proportion of mefloquine-related adverse events constitutes an important barrier to its effectiveness for malaria preventive treatment
in pregnant women.
P L A I N L A N G U A G E S U M M A R Y
Mefloquine for preventing malaria in pregnant women
What is the aim of this review?
The aim of this Cochrane Review was to find out whether the antimalarial drug mefloquine is efficacious and safe for prevention of
malaria in pregnant women living in stable transmission areas. We found six relevant studies to help us answer this question.
Key messages
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The antimalarial drug mefloquine is efficacious for malaria prevention in pregnant women. The drug has been found to be safe in
terms of adverse pregnancy outcomes, such as low birth weight, prematurity, stillbirths and abortions, and congenital malformations.
However, it is worse tolerated than other antimalarial drugs.
What was studied in the review?
Pregnant women are vulnerable to malaria infection, especially if they are living with HIV. The consequences of malaria during
pregnancy can be severe and include poor health outcomes for both women and their children. For this reason, in malaria-endemic
areas of stable transmission, women are recommended to prevent malaria infection by sleeping under mosquito bed-nets and by taking
effective drugs (such as sulphadoxine-pyrimethamine or cotrimoxazole in case of HIV infection) as chemoprevention against malaria
throughout pregnancy.
This Cochrane Review looked at the effects of mefloquine for prevention of malaria in both HIV-uninfected andHIV-infected pregnant
women.
What are the main results of the review?
We found five relevant studies conducted in sub-Saharan Africa and one in Thailand between 1987 and 2013. These studies compared
mefloquine with placebo or other antimalarial drugs currently recommended for prevention of malaria in pregnant women. The review
shows the following:
• Compared with sulfadoxine-pyrimethamine, mefloquine chemoprevention in HIV-uninfected women:
reduces risks of maternal peripheral parasitaemia (presence of malaria parasites in the blood of women) and anaemia at delivery;
makes no difference in the prevalence of adverse maternal outcomes (such as low birth weight, prematurity, stillbirths and abortions,
and congenital malformations) and in the incidence of clinical malaria episodes during pregnancy; and
increases risks of drug-related adverse events including vomiting, fatigue/weakness, and dizziness.
• Compared with cotrimoxale prophylaxis alone, mefloquine chemoprevention plus cotrimoxazole in HIV-infected women:
reduces the risk of maternal peripheral parasitaemia at delivery and the risk of placental malaria;
makes no difference in the prevalence of adverse pregnancy outcomes (such as low birth weight, prematurity, stillbirths and abortions,
and congenital malformations) and in the incidence of clinical malaria episodes during pregnancy; and
increases the risk of drug-related adverse events such as vomiting and dizziness.
Overall, the high proportion of mefloquine-related adverse events constitutes an important barrier to its effectiveness for malaria
preventive treatment in pregnant women.
How up-to-date is this review?
The review authors searched for studies up to 31 January 2018.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Mefloquine compared with sulfadoxine-pyrimethamine for preventing malaria in pregnant women
Patient or population: HIV-uninfected pregnant women
Setting: Benin, Gabon, Mozambique, and Tanzania
Intervention: mef loquine
Comparison: sulfadoxine-pyrimethamine
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments (compared
with sulfadoxine-
pyrimethamine)
Risk with sulfadoxine-
pyrimethamine
Risk with mefloquine
Clinical malaria
episodes during preg-
nancy
- - IRR 0.83
(0.65 to 1.05)
-
(2 RCTs)
⊕⊕⊕©
HIGHa
Mef loquine results in
lit t le or no dif ference in
the incidence of clinical
malaria episodes dur-
ing pregnancy
Maternal periph-
eral parasitaemia at de-
livery
43 per 1000 28 per 1000
(20 to 37)
RR 0.65
(0.48 to
0.86)
5455
(2 RCTs)
⊕⊕⊕©
HIGHa
Mef loquine results in
lower maternal periph-
eral parasitaemia at de-
livery
Placental malaria 52 per 1000 54 per 1000
(30 to 97)
RR 1.04
(0.58 to 1.86)
4668
(2 RCTs)
⊕⊕©©
LOWa,b,c
Due to imprecision and
heterogeneity
Mef loquine may result
in lit t le or no dif fer-
ence in placental para-
sitaemia
Maternal anaemia at
delivery
219 per 1000 184 per 1000
(166 to 206)
RR 0.84
(0.76 to 0.94)
5469
(2 RCTs)
⊕⊕⊕©
MODERATEa,d
Due to imprecision
Mef loquine probably re-
sults in fewer women
anaemic at delivery
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Low birth weight 117 per 1000 111 per 1000
(91 to 137)
RR 0.95
(0.78 to 1.17)
5641
(2 RCTs)
⊕⊕⊕©
HIGHa
Mef loquine results in
lit t le or no dif ference in
low birth weight
St illbirths and abor-
t ions
31 per 1000 37 per 1000
(28 to 49)
RR 1.20
(0.91 to 1.58)
6219
(2 RCTs)
⊕⊕⊕©
HIGHa
Mef loquine results in
lit t le or no dif ference in
st illbirths or abort ions
AEs: vomit ing 82 per 1000 390 per 1000
(338 to 449)
RR 4.76
(4.13 to 5.49)
6272
(2 RCTs)
⊕⊕⊕⊕
HIGHa
Mef loquine results in
a four-fold increase in
vomit ing
AEs: dizziness 94 per 1000 396 per 1000
(316 to 496)
RR 4.21
(3.36 to 5.27)
6272
(2 RCTs)
⊕⊕⊕©
HIGHa,b
Mef loquine results in
a four-fold increase in
dizziness
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: CI: conf idence interval; IRR: incidence rate rat io; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence.
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aAlthough one trial has serious risk of bias, the other is of high certainty and exclusion of the smaller trial has lit t le ef fect on
the est imate of ef fect.
bDowngraded by 1 for imprecision: Conf idence intervals range f rom considerable benef it to considerable harm.
cDowngraded by 1 for heterogeneity: Substant ive qualitat ive heterogeneity is evident in the meta-analysis.
dConf idence intervals include lit t le or no important dif f erence to a 24% reduct ion in anaemic women. The est imate of 16% is
judged to be clinically important.
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B A C K G R O U N D
Description of the condition
Malaria is the most important parasitic disease worldwide and is
endemic in parts of Africa, Asia, and South America. Pregnant
women are at higher risk of malaria infection than non-pregnant
women in the same age group, and are at higher risk of severe
illness (Brabin 1983; Desai 2007). Malaria infection during preg-
nancy, particularly the first or second pregnancy, is also associated
with adverse outcomes for both mother (severe anaemia) and in-
fant (low birth weight, neonatal mortality; Ataíde 2014; Guyatt
2004; Menendez 2010; Radeva-Petrova 2014; Schwarz 2008;
Steketee 2001). Symptoms most commonly reported by semi-im-
mune pregnant women with clinical malaria include headache,
arthromyalgias, and fever (Bardaji 2008). In areas of low trans-
mission, pregnant women with malaria parasitaemia frequently
present with symptoms and signs such as fever, malaise, headache,
and vomiting. The infection may develop into severe complica-
tions such as cerebral malaria and pulmonary oedema if untreated,
and may be a cause of maternal mortality (Bardaji 2008).
To reduce the burden and consequences of malaria in pregnancy,
the World Health Organization (WHO) currently recommends
that pregnant women who live in moderate to high malaria trans-
mission areas in Africa sleep under an insecticide-treated net
(ITN), as described in Gamble 2006, and receive intermittent pre-
ventive treatment (IPT) with sulfadoxine-pyrimethamine at each
scheduled antenatal care visit (provided that doses are at least one
month apart) (WHO 2013). IPT is a form of malaria chemo-
prevention that was tested and adopted as policy in response to
both malaria parasites developing resistance to weekly prophy-
laxis with chloroquine and low compliance with the weekly reg-
imen (WHO 2004). The long elimination half-life of sulfadox-
ine-pyrimethamine allows intermittent dosing while still provid-
ing prophylactic cover for the intervening weeks (White 2005).
IPT is therefore defined as “administration of a curative treatment
dose of an effective antimalarial drug at predefined intervals dur-
ing pregnancy” regardless of the presence or absence of current
infection (White 2005).
Sulfadoxine-pyrimethamine remains the drug used for IPT in
pregnancy, even though resistance has spread in many parts of
southern and eastern Africa (ter Kuile 2007;WHO2012a), which
is spurring researchers and policy makers to seek safe and effective
alternatives to sulfadoxine-pyrimethamine (Desai 2018).
Description of the intervention
Mefloquine is a 4-methanolquinoline that is related to quinine. It
was originally developed by the USmilitary for preventingmalaria
in soldiers and has been widely used for preventing malaria in
travellers (Schlagenhauf 2010). Like sulfadoxine-pyrimethamine,
mefloquine has a long elimination half-life of two to four weeks;
in travellers, weekly dosing consists of 250 mg (FDA 2004), and
in pregnant women monthly dosing at treatment doses is feasible
(Briand 2009).
Mefloquine was first investigated in the 1990s as prophylactic
treatment for pregnant women. An observational study raised con-
cerns that mefloquine may be associated with increased risk of
stillbirth (Nosten 1999); however other trials did not confirm this
finding (Pekyi 2016; Steketee 1996). A systematic review consid-
ered the safety of mefloquine in pregnancy and concluded that
no evidence indicates that mefloquine use in pregnancy carries
increased risk for the foetus (Gonzalez 2014). The drug is known
to be associated with a range of mild dose-related transient side
effects, such as vomiting, nausea, and dizziness (Bardaji 2012;
Lee 2017; Sevene 2010; ter Kuile 1995). Researchers have de-
scribed severe neuropsychiatric side effects that occur in about
one in 10,000 travellers taking mefloquine as chemoprophylaxis
(Phillips-Howard 1995; Steffen 1993). Studies conducted inBeni-
nese pregnant women found that dizziness and vomiting are the
most frequent adverse effects related to use of mefloquine as IPT
in pregnancy (Briand 2009; Denoeud-Ndam 2012).
Data show resistance to mefloquine in multi-drug resistance areas
of Thailand (Carrara 2009; Nosten 2000), but it remains rare in
Africa (Aubouy 2007; MacArthur 2001; Oduola 1987).
How the intervention might work
Malaria chemoprevention is thought to work through clearance or
suppression of asymptomatic malaria infection in the peripheral
blood of the mother and the placenta (White 2005). This reduc-
tion in malaria parasitaemia may, however, be insufficient to jus-
tify recommendations for widespread prophylactic prescriptions
that do not provide subsequent benefit for clinically important
outcomes for mother and baby. These outcomes may include a re-
duction in episodes of maternal malaria, reduced risk of anaemia,
and improved birth weight, as well as more substantive outcomes
such as a reduction in severe maternal illness or lower rates of
spontaneous pregnancy loss and maternal, neonatal, and infant
mortality (see Figure 1).
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Figure 1. Indicators and impact of malaria infection in mothers and infants.
Effects of malaria chemoprevention may depend on the local
malaria epidemiology and thus the level of acquired immunity
against malaria in pregnant women. In stable transmission areas,
women of reproductive age may be partially immune to malaria,
presenting parasitaemia without clinical disease; however, asymp-
tomatic infections may have detrimental effects, such as anaemia
and low birth weight. In contrast, in unstable malaria transmis-
sion areas, naturally acquired malaria immunity is usually low
among adults andmalaria infectionmay be associated with clinical
episodes and severe illness.
Primigravidae women are at higher risk of adverse effects ofmalaria
infection than multigravidae women. This is thought to result
from women developing antibodies specific to placental-type par-
asites when exposed to Plasmodium falciparum during their first
pregnancy. These antibodies are then present in subsequent preg-
nancies (Ataíde 2014). This is seen in multigravidae women as
a more specific and efficient immune response and clearing the
infection at an earlier stage than in primigravidae women (Walker
2013).
Another potential effect modifier of the susceptibility to malaria
infection is HIV status (Menéndez 2011). In many malaria-en-
demic areas, data show that the prevalence of HIV infection,
which has been observed to increase the risk of malaria infection,
is high among pregnant women (Gonzalez 2012; van Eijk 2003).
Compared with HIV-uninfected women, HIV-infected women
are more likely to carry malaria parasites in their blood, to have
higher parasite densities, and to develop placental parasitaemia,
anaemia, and malaria symptoms (Ayisi 2003; van Eijk 2002; van
Eijk 2003). This increased risk ofmalaria is the same inmultigravi-
dae (women in their third pregnancy or higher) and in women in
their first or second pregnancy (ter Kuile 2004; van Eijk 2003).
Placental malaria infection may also increase the risk of perinatal
mother-to-child transmission of HIV (Ayisi 2003).
Use of ITNs during pregnancy has been shown to have a bene-
ficial impact on pregnancy outcomes (reduced prevalence of low
birth weight, miscarriage, and placental parasitaemia) in malaria-
endemic Africa (Gamble 2007), and this approach could modify
the effect of IPT (Menéndez 2008).
Why it is important to do this review
TheWHOrecommends IPTwith sulfadoxine-pyrimethamine for
all pregnantwomenwho live inmoderate to highmalaria transmis-
sion areas in Africa (WHO 2004; WHO 2013). However, studies
have shown that resistance to sulfadoxine-pyrimethamine in some
regions of Eastern Africa has been increasing steadily during the
past two decades (Iriemenam 2012; Mockenhaupt 2008). Thus,
there is an urgent need for more effective antimalarials to prevent
malaria during pregnancy.
This review aims to evaluate the efficacy and safety of mefloquine
for preventing malaria in pregnant women. These findings could
serve as the basis for future guidelines on preventive agents for
malaria in pregnant women.
O B J E C T I V E S
To assess the effects of mefloquine for preventing malaria in preg-
nant women - specifically, to evaluate:
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• the efficacy, safety, and tolerability of mefloquine for
preventing malaria in pregnant women; and
• the impact of HIV status, gravidity, and use of insect-
treated nets (ITNs) on the effects of mefloquine.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) and quasi-RCTs.
Types of participants
Pregnant women of any gravidity regardless of HIV status, living
in malaria-endemic areas (CDC 2017).
Types of interventions
Interventions
Mefloquine given to pregnant women as intermittent preventive
treatment or as chemoprophylaxis.
Controls
Placebo, no intervention, or an alternative drug regimen.
Types of outcome measures
Maternal
• Maternal peripheral parasitaemia during pregnancy
• Maternal peripheral parasitaemia at delivery
• Placental malaria¹
• Mean haemoglobin and maternal anaemia (moderate and
severe) at delivery
• Clinical malaria episodes during pregnancy
Foetal/infant
• Cord blood parasitaemia
• Cord blood haemoglobin and anaemia (as defined in the
original studies)
• Mean birth weight
• Low birth weight prevalence (< 2500 g)
• Prematurity prevalence (< 37 weeks of gestation)
• Morbidity in first year of life
Adverse events
• Serious adverse events (SAEs)²
◦ Illnesses that were life threatening or required
hospitalization during pregnancy (SAEs in pregnancy)
◦ Adverse pregnancy outcomes: spontaneous abortion,
stillbirth, congenital malformation
◦ Maternal mortality
◦ Perinatal, neonatal, infant mortality
◦ Mother-to-child transmission of HIV frequency (at six
weeks of age)
• Non-serious adverse events
◦ Frequency and severity of reported all-cause and drug-
related adverse events
¹Placental malaria diagnosed by histology, microscopy, or any
method used in the included study. Figure 2 shows the relations
between different outcomes.
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Figure 2. Conceptual framework of malaria chemoprevention. Reproduced under the terms of a Creative
Commons Licence from Radeva-Petrova 2014.
²Review authors acknowledge the limitation of analyzing rare se-
rious adverse events because randomized controlled trials usually
are not powered enough to detect them.
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
Electronic searches
We searched the following databases using the search terms and
strategy described in Appendix 1: the Cochrane Infectious Dis-
eases Group Specialized Register (up to 31 January 2018); the
Cochrane Central Register of Controlled Trials (CENTRAL),
published in the Cochrane Library (January 2018); MEDLINE
(PubMed; from 1966 to 31 January 2018); Embase (OVID;
1974 to 31 January 2018); and Latin American Caribbean
Health Sciences Literature (LILACS) (BIREME; 1982 to 31
January 2018). We also searched the Malaria in Pregnancy
(MiP) Library (www.mip-consortium.org/resources/index.htm),
the WHO International Clinical Trial Registry Platform (IC-
TRP; www.who.int/ictrp/search/en), ClinicalTrials.gov, and the
International StandardRandomizedControlledTrialNumber (IS-
RCTN) registry (www.isrctn.com/), using ‘mefloquine’, ‘malaria’,
and ‘pregnan*’ as search terms.
Searching other resources
We contacted researchers working in the field to ask for unpub-
lished data, confidential reports, and raw data from published tri-
als. We also checked the citations of all trials identified by the
methods described.
Data collection and analysis
Selection of studies
Two review authors independently screened all trials identified by
the search strategy by title or abstract, or both (Appendix 1). We
coded studies as ‘retrieve’ or ‘do not retrieve’. We retrieved the
full-text copies of trials deemed potentially relevant. Two review
authors then independently assessed study eligibility using a form
based on the review inclusion criteria. We resolved disagreements
through discussion or by consultation with a third review author.
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Any review author who participated in trials that potentially met
the review inclusion criteria did not participate in the procedure to
select studies for inclusion. We listed all studies excluded after full-
text assessment and reasons for their exclusion in a ‘Characteristics
of excluded studies’ table.We illustrated the study selectionprocess
in a PRISMA diagram.
Data extraction and management
Three review authors (RG, CPD, and MP) used a data extrac-
tion form to independently extract data on trial characteristics,
including trial site, year, local malaria transmission estimates, anti-
malarial resistance pattern of mefloquine and the comparator drug
(when possible), trial methods, participants, interventions, doses,
and outcomes.
We extracted the number of participants randomized and the num-
ber of participants analyzed in experimental and control groups
for each outcome. For dichotomous outcomes, we extracted the
number of participants experiencing the event and the number
assessed in each treatment group. For continuous outcomes, we
extracted the arithmetic means, standard deviations for each treat-
ment group (when provided), and the number of participants as-
sessed in each group. We also extracted medians and ranges when
provided. For outcomes reported as incidences, we extracted the
number of participants experiencing the event (cases) and the per-
son-years at risk.
Any review author who participated in any of the trials included
in the review did not participate in data extraction nor ‘Risk of
bias’ assessment of their own articles.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias for each
included trial using the Cochrane ‘Risk of bias’ assessment tool
(Higgins 2011). This approach assesses the risk of bias across seven
domains: sequence generation, allocation concealment, blinding
of participants and personnel, blinding of outcome assessment,
incomplete outcome data, selective outcome reporting, and other
potential sources of bias (Higgins 2011). For each domain, we
assigned a judgment of low, high, or unclear risk of bias. We
judged the risk of bias for blinding on the presence of blinding and
whether lack of blinding could potentially influence the results.
Measures of treatment effect
We presented dichotomous outcomes using risk ratios (RRs),
count outcomes as incidence rate ratios (IRRs), and continuous
outcomes as mean differences (MDs). We presented all measures
of effect with 95% confidence intervals (CIs).
Unit of analysis issues
When conducting a meta-analysis, we ensured that participants
and cases in the placebo group were not counted more than once.
Dealing with missing data
We aimed to conduct the analysis according to the intention-to-
treat principle. However, when there was loss to follow-up, we
used a complete-case analysis such that participants for whom no
outcome was reported were excluded from the analysis. This anal-
ysis assumes that participants for whom an outcome is available
are representative of the original randomized patients. We aimed
to conduct a sensitivity analysis to evaluate the robustness of this
method, but this was not possible, as described below. If data from
trial reports were insufficient, unclear, or missing, we contacted
the study authors for additional information.
Assessment of heterogeneity
We calculated the I2 statistic using values of 30% to 59%, 60%
to 89%, and 90% to 100% to denote moderate, substantial, and
considerable levels of heterogeneity, respectively.
Assessment of reporting biases
We aimed to assess the risk of publication bias by constructing
funnel plots and looking for asymmetry, but the small number of
trials included in each comparison of the meta-analysis made this
assessment impossible.
Data synthesis
We performed data analysis using Review Manager 5 (RevMan 5)
(RevMan 2014). We intended to perform subgroup analysis by
gravidity andHIV statuswhenpossible.HIV status subgroup anal-
ysis was not possible in any case owing to different study designs
for differentHIV status populations. In the absence of heterogene-
ity, we used a fixed-effect model for the meta-analysis; when we
detected moderate or considerable heterogeneity, we used a ran-
dom-effects model. Additionally, we assessed the certainty of evi-
dence using the GRADE approach (GRADEpro GDT 2015) for
the following main outcomes of analysis: maternal peripheral par-
asitaemia at delivery, clinical malaria episodes during pregnancy,
placental malaria, maternal anaemia at delivery, low birth weight,
spontaneous abortion and stillbirth, dizziness, and vomiting.
Subgroup analysis and investigation of heterogeneity
We aimed to investigate heterogeneity by conducting prespecified
subgroup analysis to evaluate the contributions of differences in
trial characteristics such as risk of bias, geographical region,malaria
transmission pattern, antimalarial resistance, drug regimen, use
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of ITNs, gravidity (primigravidae versus multigravidae), HIV sta-
tus (uninfected, infected, unknown), and trial methods. Only the
gravidity subgroup analysis was possible for one outcome of the
main comparison. The other subgroup analyses were not possible
because of the small number of trials included in each comparison.
Sensitivity analysis
Weplanned to conduct a sensitivity analysis to restore the integrity
of the randomization process and to test the robustness of our
results; however, the small number of trials included in each com-
parison - two at most - made this impossible. Additionally, miss-
ing outcome data were balanced in numbers across intervention
groups, and reasons for missing data were similar across groups.
R E S U L T S
Description of studies
Results of the search
The literature search, conducted up to 31 January 2018, identified
254 references, of which two were duplicate trial reports. Of the
252 remaining articles, we excluded 231 articles and one ongoing
trial after title/abstract screening. We assessed 20 full-text articles
for eligibility, of which we excluded 14 articles. Six trials (in six
publications) met the inclusion criteria of the review (Figure 3).
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Figure 3. Study flow diagram.
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Included studies
Six chemoprevention trials that included 8192 pregnant women
met our inclusion criteria (see the Characteristics of included
studies section). These trials were conducted between 1987 and
2013 in Thailand (one trial), Benin (three trials), Gabon (one
trial), Kenya (one trial), Mozambique (two trials), and Tanzania
(two trials).
The included trials recruited women of all gravidities of all ages
(four trials) or over 18 years of age (two trials). Gestational age at
recruitment was greater than 20 weeks (one trial), between 16 and
28 weeks (three trials), or ≤ 28 weeks (two trials).
Two trials evaluated mefloquine against sulfadox-
ine-pyrimethamine as IPTp in HIV-uninfected pregnant women.
Three trials evaluated mefloquine IPTp alone (or in combination
with daily cotrimoxazole) against cotrimoxazole in HIV-infected
pregnant women. Finally, one trial in Thailand compared weekly
mefloquine prophylaxis against placebo in women of unknown
HIV status. All included trials reported that drug administration
was supervised.
All included trials recruited women in all gravidity groups; five
reported aggregate results and one disaggregated by gravidity for
the primary outcome. In five trials, all women in both intervention
and control groups received a long-lasting ITN at recruitment and
iron, and investigators routinely administered folic acid.
Excluded studies
We excluded one trial for the reasons given in the ‘Characteristics
of excluded studies’ table.
Risk of bias in included studies
See Figure 4 and Figure 5 for a summary of the ‘Risk of bias’ assess-
ments. We have presented further details in the ‘Characteristics of
included studies’ table.
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Figure 4. ‘Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 5. ‘Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Random sequence generation (selection bias)
Two trials adequately described methods of sequence generation
(Gonzalez 2014a BEN GAB MOZ TAN; Gonzalez 2014b KEN
MOZ TAN), three described a non-random component in the
sequence generation process (Briand 2009 BEN; Denoeud-Ndam
2014a BEN; Denoeud-Ndam 2014b BEN), and in the remaining
trial, the risk was unclear (Nosten 1994 THA).
Allocation concealment (selection bias)
Four trials described adequate methods of allocation concealment
(Denoeud-Ndam 2014a BEN; Denoeud-Ndam 2014b BEN;
Gonzalez 2014a BEN GAB MOZ TAN; Gonzalez 2014b KEN
MOZ TAN), one trial reported no concealment of allocation
(Briand 2009 BEN), and in the remaining trial, the risk was un-
clear (Nosten 1994 THA).
Blinding
Blinding of participants and personnel (performance bias)
Four trials were open (Briand 2009 BEN; Denoeud-Ndam 2014a
BEN; Denoeud-Ndam 2014b BEN; Gonzalez 2014a BEN GAB
MOZ TAN), and we assessed these as having high risk of perfor-
mance risk. Two trials were double-blind and placebo-controlled
(Gonzalez 2014b KENMOZ TAN; Nosten 1994 THA), and we
assessed these as having low risk of performance bias.
Blinding of efficacy outcome assessment (detection bias)
For five trials, we judged the efficacy outcome as not influenced
by blinding or lack of blinding. In the remaining trial, the risk
of detection bias for efficacy outcomes was unclear (Nosten 1994
THA).
Blinding of safety outcome assessment (detection bias)
For the four open trials, we judged the risk of detection bias
as high for assessment of safety outcomes (Briand 2009 BEN;
Denoeud-Ndam 2014a BEN; Denoeud-Ndam 2014b BEN;
Gonzalez 2014a BEN GAB MOZ TAN). In one trial, the risk of
detection bias was unclear (Nosten 1994 THA). For the remaining
trial, which was double-blinded, we judged the risk of detection
bias as low (Gonzalez 2014b KEN MOZ TAN).
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Incomplete outcome data
In all included trials, missing outcome data were balanced in num-
bers across groups, and we judged the risk of attrition bias to be
low.
Selective reporting
We considered the risk of reporting bias as low in five trials and
unclear in one (Nosten 1994 THA).
Other potential sources of bias
All included trials appeared to be free of other sources of bias, and
we judged this risk as low.
Effects of interventions
See: Summary of findings for the main comparisonMefloquine
compared with sulfadoxine-pyrimethamine for preventingmalaria
in pregnant women; Summary of findings 2 Mefloquine
plus cotrimoxazole compared with cotrimoxazole for preventing
malaria in pregnant women
Comparison 1: Mefloquine versus sulfadoxine-
pyrimethamine (HIV-uninfected pregnant women)
See Summary of findings for the main comparison.
Maternal outcomes
We included in this comparison two trials that evaluated two doses
of IPTp (Briand 2009 BEN; Gonzalez 2014a BEN GAB MOZ
TAN). Data show a decrease in the number of clinical malaria
episodes during pregnancy among mefloquine recipients, but this
does not clearly constitute an effect ofmefloquine because the 95%
CIs do not exclude the possibility of no different effects (IRR 0.83,
95% CI 0.65 to 1.05; 2 studies; high-certainty evidence; Analysis
1.1). Overall, IPTp-mefloquine was associated with a 35% reduc-
tion in the risk of maternal peripheral parasitaemia at delivery (RR
0.65, 95%CI 0.48 to 0.86; 5455 participants, 2 studies; I2 statistic
= 16%;moderate-certainty evidence; Analysis 1.2), but the absolute
difference between treatments was small. We found no significant
evidence of an effect of mefloquine or sulfadoxine-pyrimethamine
on placental malaria infections (RR 1.04, 95% CI 0.58 to 1.86;
4668 participants, 2 studies; I2 statistic = 63%; low-certainty ev-
idence; Analysis 1.3). The mefloquine group showed a slight in-
crease in the mean haemoglobin level at delivery (MD 0.10, 95%
CI 0.01 to 0.19; 5588 participants, 2 studies; I2 statistic = 0%;
Analysis 1.4) and a decrease in maternal anaemia cases at delivery
(RR 0.84, 95% CI 0.76 to 0.94; 5469 participants, 2 studies; I2
statistic = 0%; moderate-certainty evidence; Analysis 1.5), but the
data show no significant differences in severe maternal anaemia at
delivery between groups (RR 0.93, 95% CI 0.58 to 1.48; 5469
participants, 2 studies; I2 statistic = 41%; Analysis 1.6). The origi-
nal definitions of maternal moderate anaemia and severe maternal
anaemia were different in the two trials included in the analysis
(Gonzalez 2014a BEN GABMOZ TAN defined anaemia as hae-
moglobin < 11 g/dL and severe anaemia as haemoglobin < 7 g/
dL), but we homogenized data for the analysis as < 9.5 g/dL and
< 8 g/dL (as defined in Briand 2009 BEN), respectively.
Foetal/infant outcomes
No effect was evident for the outcomes of cord blood parasitaemia
(RR 0.44, 95% CI 0.13 to 1.46; 5309 participants, 2 studies; I2
statistic = 33%; Analysis 1.7) and cord blood anaemia (RR 1.04,
95% CI 0.87 to 1.23; 4006 participants, 1 study; Analysis 1.8).
Regarding newborn outcomes, mean birth weight did not show
significant differences between groups (MD 2.52, 95% CI -25.66
to 30.69; 5241 participants, 2 studies; I2 statistic = 0%; Analysis
1.9). Low birth weight (RR 0.95, 95% CI 0.78 to 1.17; 5641 par-
ticipants, 2 studies; I2 statistic = 33%; moderate-certainty evidence;
Analysis 1.10) and prematurity prevalence (RR 1.03, 95%CI 0.76
to 1.40; 4640 participants, 2 studies; I2 statistic = 0%; Analysis
1.12) also showed no differences between groups. Subgroup anal-
ysis of low birth weight by gravidity yielded results that did not
vary (primigravidae: RR 1.02, 95% CI 0.80 to 1.30; 1576 partic-
ipants, 2 studies; I2 statistic = 3%; Analysis 1.11; multigravidae:
RR 0.94, 95% CI 0.78 to 1.14; 4065 participants, 2 studies; I2
statistic = 0%; Analysis 1.11).
Only one trial reported data on infant morbidity, and results fol-
lowed the same trend; the IRR was near 1, and the CIs did not
discard the possibility of no difference between mefloquine and
sulfadoxine-pyrimethamine. Chosen proxies for infant morbidity
were malaria in the first year of life (IRR 0.97, 95% CI 0.82 to
1.15; 1 study; Analysis 1.13) and hospital admissions in the first
year of life (IRR 0.93, 95% CI 0.75 to 1.17; 1 study; Analysis
1.14).
Safety outcomes
No difference was evident between mefloquine and sulfadoxine-
pyrimethamine in overall serious adverse events reporting (RR
0.98, 95% CI 0.81 to 1.20; 4674 participants, 1 study; Analysis
1.15). Definitions of stillbirth and abortion were different for the
two trials included in this comparison; therefore we aggregated
both outcomes into a single outcome (RR 1.20, 95% CI 0.91
to 1.58; 6219 participants, 2 studies; I2 statistic = 0%; moderate-
certainty evidence; Analysis 1.16). Congenital malformation cases
were also similar in both intervention groups (RR 1.10, 95% CI
0.51 to 2.37; 5931 participants, 2 studies; I2 statistic = 33%;
Analysis 1.17).
Regarding maternal mortality, one of the trials reported maternal
deaths only in the mefloquine group, and the other trial showed
a similar proportion of maternal deaths in both IPTp groups; the
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CI of the meta-analysis was wide, and heterogeneity was moderate
(RR 2.41, 95% CI 0.27 to 21.23; 6219 participants, 2 studies; I
2 statistic = 54%; Analysis 1.18). Only one of the trials reported
neonatal and infant mortality (Gonzalez 2014a BEN GABMOZ
TAN), but we obtained neonatal mortality rates for the other
trial by contacting the study authors (Briand 2009 BEN). Neither
of the two outcomes showed a significant effect of mefloquine
or sulfadoxine-pyrimethamine (neonatal deaths: RR 0.98, 95%
CI 0.67 to 1.43; 6134 participants, 2 studies; I2 statistic = 0%;
Analysis 1.19; incidence of infant deaths: IRR 1.00, 95% CI 0.66
to 1.52; 1 study; Analysis 1.20).
Overall, IPTp-mefloquine increased the risk of adverse events; re-
sults of individual trials and of meta-analyses were significant for
vomiting (RR 4.76, 95% CI 4.13 to 5.49; 6272 participants, 2
studies; I2 statistic = 0%; high-certainty evidence; Analysis 1.21),
fatigue/weakness (RR 4.62, 95% CI 1.80 to 11.85; 6272 partici-
pants, 2 studies; I2 statistic = 91%; high-certainty evidence; Analysis
1.22), and dizziness (RR 4.21, 95% CI 3.36 to 5.27; 6272 par-
ticipants, 2 studies; I2 statistic = 66%; moderate-certainty evidence;
Analysis 1.23), with the exception of headache (RR 0.70, 95%
CI 0.25 to 1.94; 6272 participants, 2 studies; I2 statistic = 85%;
Analysis 1.24).
Comparison 2: Mefloquine plus cotrimoxazole versus
cotrimoxazole (HIV-infected pregnant women)
See Summary of findings 2.
Maternal outcomes
This comparison included two trials evaluating three IPTp doses
of mefloquine (Denoeud-Ndam 2014a BEN; Gonzalez 2014b
KENMOZTAN). Only one of the trials reported clinical malaria
episodes during pregnancy, noting no significant differences in
malaria episodes between groups (IRR 0.76, 95%CI 0.33 to 1.76;
1 study; high certainty evidence; Analysis 2.1). IPTp-mefloquine
plus cotrimoxazole prophylaxis was associated with a 48% reduc-
tion in the risk of maternal peripheral parasitaemia at delivery
measured by polymerase chain reaction (PCR) (RR 0.52, 95%
CI 0.30 to 0.93; 989 participants, 2 studies; I2 statistic = 0%;
moderate-certainty evidence; Analysis 2.2), a 49% reduction in the
risk of placental malaria measured by blood smear (RR 0.51, 95%
CI 0.29 to 0.89; 1144 participants, 2 studies; I2 statistic = 0%;
Analysis 2.3), and a 72% reduction in the risk of placental malaria
measured by PCR (RR 0.28, 95% CI 0.14 to 0.57; 977 partici-
pants, 2 studies; I2 statistic = 0%; high-certainty evidence; Analysis
2.4). The other maternal-related outcomes at delivery included in
this comparison did not show evidence that they were effects of
mefloquine owing to the wideness of the CIs (mean haemoglobin:
MD 0.07, 95% CI -0.32 to 0.46; 1167 participants, 2 studies; I
2 statistic = 62%; Analysis 2.5; maternal anaemia: RR 0.94, 95%
CI 0.73 to 1.20; 1197 participants, 2 studies; I2 statistic = 12%;
moderate-certainty evidence; Analysis 2.6; severe maternal anaemia:
RR 0.93, 95% CI 0.41 to 2.08; 1167 participants, 2 studies; I2
statistic = 0%; Analysis 2.7). The original definitions of maternal
anaemia were different in the two trials included in the analysis
(Gonzalez 2014b KENMOZTANdefined anaemia as haemoglo-
bin < 11 g/dL), but we homogenized definitions for the analysis
as < 9.5 g/dL (as defined in Denoeud-Ndam 2014a BEN). The
two trials defined severe maternal anaemia as haemoglobin < 7 g/
dL.
Foetal/infant outcomes
Meta-analyses of foetal and neonatal outcomes were underpow-
ered to detect significant effects of mefloquine on cord blood par-
asitaemia (RR 0.33, 95% CI 0.03 to 3.13; 1166 participants, 2
studies; I2 statistic = 0%; Analysis 2.8), mean birth weight (MD
-25.75, 95% CI -86.99 to 35.49; 1220 participants, 2 studies; I
2 statistic = 0%; Analysis 2.9), low birth weight rates (RR 1.20,
95% CI 0.89 to 1.60; 1220 participants, 2 studies; I2 statistic =
0%; moderate-certainty evidence; Analysis 2.10), and prematurity
rates (RR 1.07, 95% CI 0.58 to 1.72; 824 participants, 2 studies;
I2 statistic = 32%; Analysis 2.11). These CIs did not exclude the
possibility of no different effects between groups.
Safety outcomes
Overall, serious adverse events during pregnancywere significantly
less frequent in the group of IPTp-mefloquine plus cotrimoxazole
prophylaxis than in the cotrimoxazole alone group (RR 0.69, 95%
CI 0.50 to 0.95; 1347 participants, 2 studies; I2 statistic = 0%;
Analysis 2.12). However, analysis of individual adverse events did
not show differences between groups, for example, spontaneous
abortions and stillbirths (RR 1.12, 95% CI 0.42 to 2.98; 1347
participants, 2 studies; I2 statistic = 69%; very low-certainty ev-
idence; Analysis 2.13) and congenital malformations (RR 0.61,
95% CI 0.22 to 1.67; 1312 participants, 2 studies; I2 statistic =
0%; Analysis 2.14). Definitions of spontaneous abortion and still-
birth were different in the two included trials (that is, difference in
the gestational age cutoff for classifying miscarriage or stillbirth);
therefore, we combined both indicators and analyzed them as one.
Only one trial included information onmaternal deaths (Gonzalez
2014b KEN MOZ TAN), and we obtained this information by
contacting the authors in the other trial (Denoeud-Ndam 2014a
BEN). Analyses of maternal deaths revealed no significant dif-
ferences between groups (RR 0.51, 95% CI 0.13 to 2.01; 1347
participants, 2 studies; I2 statistic = 0%; Analysis 2.15). Also, we
found that neonatal mortality rates were not significantly differ-
ent among groups, as revealed by the CI (RR 1.32, 95% CI 0.65
to 2.69; 1239 participants, 2 studies; I2 statistic = 0%; Analysis
2.16). It is important to note that mefloquine plus cotrimoxazole
recipients were at 1.92 times greater risk of mother-to-child trans-
mission of HIV than the group that took only cotrimoxazole (RR
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1.92, 95% CI 1.13 to 3.25; 1019 participants, 2 studies; I2 statis-
tic = 0%; Analysis 2.17).
Vomiting, fatigue/weakness, and dizziness displayed substantial
and considerable levels of heterogeneity in themeta-analysis. Indi-
vidual trials showed significant increases in three drug-related ad-
verse events in the groups given IPTp-mefloquine plus cotrimox-
azole prophylaxis, but random-effects analyses show a significant
effect of IPTp-mefloquine only in the case of vomiting (RR 20.88,
95% CI 1.40 to 311.66; 1347 participants, 2 studies; I2 statistic
= 74%; Analysis 2.18), while fatigue (RR 2.95, 95% CI 0.26 to
32.93; 1347 participants, 2 studies; I2 statistic = 91%; Analysis
2.19) and dizziness (RR 16.34, 95% CI 0.39 to 684.99; 1347
participants, 2 studies; I2 statistic = 86%; Analysis 2.20) show no
significant evidence. In the three cases, CIs are considerably wide.
Headache cases were not significantly different across groups (RR
0.76, 95% CI 0.28 to 2.10; 1347 participants, 2 studies; I2 statis-
tic = 30%; Analysis 2.21).
Comparison 3: Mefloquine versus cotrimoxazole
(HIV-infected pregnant women)
Maternal outcomes
Only one trial conducted in Benin provided data on this com-
parison of three IPTp-mefloquine doses versus cotrimoxazole pro-
phylaxis (Denoeud-Ndam 2014b BEN). The few observations re-
ported in the trial made the analyses, in general, underpowered
to detect differences between groups. Efficacy outcomes directly
related to malaria yielded RR indicating beneficial effects of IPTp-
mefloquine in reducing infection, but CIs did not exclude the
possibility of no difference between groups (maternal peripheral
parasitaemia during pregnancy measured by PCR: RR 0.21, 95%
CI 0.03 to 1.72; 98 participants, 1 study; Analysis 3.1; placental
malaria measured by PCR: RR 0.73, 95% CI 0.13 to 4.15; 94
participants, 1 study; Analysis 3.2; placental malaria measured by
blood smear: RR 0.35, 95% CI 0.01 to 8.30; 108 participants, 1
study; Analysis 3.3). Data show no differences across groups for
mean haemoglobin (MD -0.10, 95%CI -0.67 to 0.47; 100 partic-
ipants, 1 study; Analysis 3.4) or maternal anaemia at delivery (RR
0.90, 95% CI 0.26 to 3.16; 100 participants, 1 study; Analysis
3.5).
Foetal/infant outcomes
All newborn outcomes included in the trial displayed wide CIs,
providing no evidence of differences between groups (mean birth
weight:MD -102.00, 95%CI -255.52 to 51.52; 120 participants,
1 study; Analysis 3.6; low birth weight rate: RR 1.52, 95% CI
0.56 to 4.13; 120 participants, 1 study; Analysis 3.7; prematurity
rate: RR 1.08, 95% CI 0.33 to 3.56; 125 participants, 1 study;
Analysis 3.8).
Safety outcomes
Serious adverse events reported in the trial were balanced across
groups and were infrequent. The CIs reveal the possibility of no
different effects between interventions in overall serious adverse
events (RR 1.06, 95% CI 0.28 to 4.07; 140 participants, 1 study;
Analysis 3.9), stillbirths (RR 4.30, 95% CI 0.49 to 37.49; 139
participants, 1 study; Analysis 3.10), spontaneous abortions (RR
1.07, 95% CI 0.07 to 16.84; 139 participants, 1 study; Analysis
3.11), and congenital malformations (RR 1.07, 95% CI 0.16 to
7.41; 139participants, 1 study; Analysis 3.12).Nomaternal deaths
occurred during the trial (139 participants, 1 study; Analysis 3.13),
and only one neonate in each intervention group died (RR 1.05,
95% CI 0.07 to 16.39; 129 participants, 1 study; Analysis 3.14).
The trial did not record infantmortality and regarded infant deaths
after seven days of birth until six weeks of age as a proxy; small
numbers of observations and infant deaths made demonstration
of differences between groups impossible (RR 2.10, 95% CI 0.19
to 22.54; 129 participants, 1 study; Analysis 3.15).
Drug-related adverse events were significantly more frequent in
the mefloquine group. Despite wide CIs, results show an effect of
mefloquine in increasing the frequency of vomiting (RR 13.43,
95% CI 3.31 to 54.54; 139 participants, 1 study; Analysis 3.16),
fatigue/weakness (RR 6.99, 95% CI 1.64 to 29.81; 139 partici-
pants, 1 study; Analysis 3.17), and dizziness (RR 52.60, 95% CI
3.26 to 848.24; 139 participants, 1 study; Analysis 3.18). Data
show no differences between groups in drug-related headache (RR
0.21, 95% CI 0.01 to 4.39; 139 participants, 1 study; Analysis
3.19).
Comparison 4: Mefloquine versus placebo (pregnant
women of unknown HIV status)
Maternal and foetal/infant outcomes
Only one trial provided data on this comparison, which comprised
two phases of mefloquine prophylaxis with different doses of the
drug (Nosten 1994 THA); the results belong to the pooled sam-
ples of both trial phases. This trial did not report clinical malaria
episodes during pregnancy, maternal anaemia at delivery, cord
blood parasitaemia and anaemia, serious adverse events, neonatal
mortality, and adverse events, or data reporting was incomplete.
The only observed significant effect that could be attributed to
mefloquine was the decrease in maternal peripheral parasitaemia
at delivery (RR 0.13, 95% CI 0.05 to 0.33; 339 participants, 1
study; Analysis 4.1). The other efficacy outcomes evaluated in this
trial - bothmaternal and newborn-related outcomes - showedwide
CIs and did not demonstrate different effects between placebo
and mefloquine prophylaxis (placental malaria: RR 0.14, 95% CI
0.01 to 2.68; 220 participants, 1 study; Analysis 4.2; mean birth
weight: MD -80.00, 95% CI -184.65 to 24.65; 290 participants,
1 study; Analysis 4.3; low birth weight: RR 1.39, 95% CI 0.78
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to 2.48; 290 participants, 1 study; Analysis 4.4; prematurity: RR
0.48, 95% CI 0.15 to 1.53; 199 participants, 1 study; Analysis
4.5).
Safety outcomes
This trial reported only serious adverse events, and adverse events
data were not complete in the published article. Stillbirths were
more prevalent in the group given mefloquine prophylaxis, but
the small number of observed events made the analysis unpow-
ered to detect differences between groups (RR 2.63, 95% CI 0.86
to 8.08; 311 participants, 1 study; Analysis 4.6). Investigators re-
ported only three spontaneous abortions and five congenital mal-
formations, thus the CIs of analyses were very wide to detect dif-
ferences in effects (spontaneous abortion: RR 0.48, 95% CI 0.04
to 5.22; 311 participants, 1 study; Analysis 4.7; congenital mal-
formation: RR 3.82, 95% CI 0.43 to 33.83; 311 participants, 1
study; Analysis 4.8). During the trial, only one maternal death
occurred in the mefloquine group, but the power of the analysis
was too low to attribute the effects to an intervention (RR 2.95,
95% CI 0.12 to 71.85; 339 participants, 1 study; Analysis 4.9).
Infant deaths were equally frequent in both trial groups (RR 1.04,
95% CI 0.63 to 1.74; 288 participants, 1 study; Analysis 4.10).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Mefloquine plus cotrimoxazole compared with cotrimoxazole for preventing malaria in pregnant women
Patient or population: HIV-infected pregnant women
Setting: Benin, Kenya, Mozambique, and Tanzania
Intervention: mef loquine plus cotrimoxazole
Comparison: cotrimoxazole
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments (compared
with cotrimoxazole)
Risk with cotrimoxa-
zole
Risk with mefloquine
plus cotrimoxazole
Clinical malaria
episodes during preg-
nancy
- - IRR 0.76 (0.33 to 1.76) -
(1 RCT)
⊕⊕⊕⊕
HIGH
Mef loquine results in
lit t le or no dif ference in
the incidence of clinical
malaria episodes dur-
ing pregnancy
Maternal periph-
eral parasitaemia at de-
livery (PCR)
66 per 1000 34 per 1000
(20 to 62)
RR 0.52
(0.30 to 0.93)
989
(2 RCTs)
⊕⊕⊕©
MODERATEa
Mef loquine probably re-
sults in lower ma-
ternal peripheral para-
sitaemia at delivery
Placental malaria
(PCR)
68 per 1000 19 per 1000
(10 to 39)
RR 0.28
(0.14 to 0.57)
977
(2 RCTs)
⊕⊕⊕⊕
HIGHa
Mef loquine plus cot-
rimoxazole results in
fewer women with pla-
cental malaria at deliv-
ery
Maternal anaemia at
delivery
178 per 1000 168 per 1000
(130 to 214)
RR 0.94
(0.73 to 1.20)
1197
(2 RCTs)
⊕⊕⊕©
MODERATEa
Mef loquine plus cotri-
moxazole probably re-
sults in lit t le or no
dif ference in maternal
anaemia cases at deliv-
ery20
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Low birth weight 118 per 1000 141 per 1000
(105 to 188)
RR 1.20
(0.89 to 1.60)
1220
(2 RCTs)
⊕⊕⊕©
MODERATEa
Mef loquine plus cotri-
moxazole probably re-
sults in lit t le or no
dif ference in low birth
weight
Spontaneous abort ions
and st illbirths
50 per 1000 56 per 1000
(21 to 149)
RR 1.12
(0.42 to 2.98)
1347
(2 RCTs)
⊕©©©
VERY LOWa,b,c
Mef loquine plus cotri-
moxazole may result in
lit t le or no dif ference in
spontaneous abort ions
and st illbirths
AEs: vomit ing 30 per 1000 239 per 1000
(144 to 396)
RR 7.95
(4.79 to 13.18)
1055
(1 RCT)d
⊕⊕⊕⊕
HIGH
Mef loquine plus cotri-
moxazole results in an
eight-fold increase in
vomit ing
AEs: dizziness 75 per 1000 296 per 1000
(214 to 411)
RR 3.94
(2.85 to 5.46)
1055
(1 RCT)e
⊕⊕⊕⊕
HIGH
Mef loquine plus cot-
rimoxazole results in
a four-fold increase in
dizziness
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: CI: conf idence interval; IRR: incidence rate rat io; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence.
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aAlthough one trial has serious risk of bias, the other is of high certainty and exclusion of the smaller trial has lit t le ef fect on
the est imate of ef fect.
bDowngraded by 1 for inconsistency: Trials showed substant ial heterogeneity.
cDowngraded by 1 for imprecision: Conf idence intervals range f rom considerable benef it to considerable harm.
dA second RCT, Denoeud-Ndam 2014a BEN, reported 50 events in the mef loquine+cotrimoxazole group and 0 in the control
group (cotrimoxazole), with RR 101 (95% CI 6.29 to 1621.68). This trial was open and part icipants knew to which group they
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were allocated. Meta-analysis causes a paradoxically very wide CI. Because of this distort ion, we have used the results f rom
Gonzalez 2014b KEN MOZ TAN in the grade table.
eA second RCT, Denoeud-Ndam 2014a BEN, reported 52 events in the mef loquine+cotrimoxazole group and 0 in the control
group (cotrimoxazole), with RR 105 (95% CI 6.54 to 1685.03). This trial was open and part icipants knew to which group they
were allocated. Meta-analysis causes a paradoxically very wide CI with the lower 95% CI. Because of this distort ion, we have
used the results f rom Gonzalez 2014b KEN MOZ TAN in this ‘Summary of f indings’ table.
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D I S C U S S I O N
Summary of main results
We included in this Cochrane Review six trials, enrolling 8192
pregnant women.
For HIV-uninfected women, two doses of intermittent preven-
tive mefloquine treatment in pregnancy (IPTp-mefloquine) re-
duced the risk of maternal peripheral parasitaemia at delivery by
35% (moderate-certainty evidence) and the risk of anaemia by 16%
(moderate-certainty evidence) compared with two doses of inter-
mittent preventive sulfadoxine-pyrimethamine treatment in preg-
nancy (IPTp-sulfadoxine-pyrimethamine). Investigators have re-
ported no significant evidence of an effect of mefloquine on pla-
cental malaria, cord blood parasitaemia and anaemia, mean birth
weight, prevalence of low birth weight, prematurity, stillbirths and
abortions, and congenital malformations. Overall, IPTp-meflo-
quine increases by approximately four-fold the risk of drug-related
adverse events including vomiting, fatigue/weakness, and dizzi-
ness (moderate-certainty evidence), when compared with sulfadox-
ine-pyrimethamine.
For HIV-infected women, three doses of IPTp-mefloquine plus
cotrimoxazole prophylaxis compared with cotrimoxazole alone
reduced the risk of maternal peripheral parasitaemia at delivery
(measured by polymerase chain reaction (PCR)) by 48% (moder-
ate-certainty evidence) and the risk of placental malaria (measured
by PCR) by 72% (high-certainty evidence).Meta-analyses were un-
derpowered to detect differences between effects of mefloquine
plus cotrimoxazole and cotrimoxazole on other maternal, foetal,
and neonatal outcomes. Regarding drug-related adverse events,
random-effects analyses showed a significant effect of IPTp-meflo-
quine plus cotrimoxazole prophylaxis compared with cotrimoxa-
zole alone only in the case of vomiting (RR 20.88, 95% CI 1.40
to 311.66; 1347 participants; low-certainty evidence). It is impor-
tant to note that mefloquine plus cotrimoxazole recipients were
at 1.92 times greater risk of mother-to-child transmission of HIV
than the group that received cotrimoxazole alone (RR 1.92, 95%
CI 1.13 to 3.25; 1019 participants). A secondary analysis of one
of the included trials revealed this finding (Gonzalez 2014b KEN
MOZ TAN).
One trial among HIV-infected women comparing three doses of
IPTp-mefloquine and cotrimoxazole was underpowered to detect
an effect of mefloquine on maternal, foetal, infant, and safety
outcomes, except for drug-related adverse events, whichweremore
frequent in the mefloquine group.
Finally, the single trial conducted in Thailand (where Plasmodium
vivax coexists) found a significant effect attributable to mefloquine
weekly prophylaxis (compared with placebo) only in reducing the
risk of maternal peripheral parasitaemia at delivery (RR 0.13, 95%
CI 0.05 to 0.33; 339 participants).
Overall completeness and applicability of
evidence
Trials were carried out in sub-Saharan Africa, except for one con-
ducted in Thailand, and were published between 1994 and 2014.
Findings evidenced that mefloquine chemoprevention reduces the
risk of maternal parasitaemia at delivery in both HIV-uninfected
and HIV-infected women compared with other antimalarials or
placebo. Additionally, in HIV-infected women, Mefloquine was
found to reduce the risk of placentalmalaria. Results from these tri-
als show fairly consistent clinically important benefits for women
and their infants. However, the risk of drug-related adverse events
was increased among mefloquine recipients, and it is notable that
mefloquine increased the risk of mother-to-child transmission in
one trial.
Included trials evaluated two or three IPTp doses of sulfadoxine-
pyrimethamine as per World Health Organization (WHO) rec-
ommendations, whereas current evidence suggests that monthly
doses may provide a better prophylactic effect (Kayentao 2013).
Additionally, the WHO currently recommends IPTp administra-
tion at each scheduled antenatal contact (WHO 2012b).
The findings of this review, derived from a variety of sub-Saharan
African settings and comparing mefloquine chemoprevention in
pregnancy with varied antimalarial drugs and placebo, may be ap-
pliedworldwide.Mefloquine is currently recommended asmalaria
chemoprevention for pregnant women of all gestational ages trav-
elling to malaria-endemic areas (CDC 2016). This drug is also
recommended for treatment of uncomplicated malaria episodes in
combination with artesunate (WHO 2015), and a fixed-dose for-
mulation is available in some malaria-endemic countries. In 2013,
the WHO Evidence Review Group (ERG) on IPTp met to assess
evidence obtained from IPTp-mefloquine trials, and the WHO
Malaria Policy Advisory Committee (MPAC) reviewed ERG rec-
ommendations and agreed that mefloquine at the 15-mg/kg dose
regimen should not be recommended for IPTp, given its adverse
events and poor tolerability (WHO MPAC 2013).
Quality of the evidence
We assessed the certainty of evidence in this review by using the
GRADE approach and presented the evidence in two ‘Summary
of findings’ tables for efficacy and safety outcomes (Summary of
findings for the main comparison; Summary of findings 2).
For HIV-uninfected pregnant women, evidence that IPTp-meflo-
quine was superior to IPTp-sulfadoxine-pyrimethamine in reduc-
ing the risk of maternal peripheral parasitaemia and anaemia at
delivery was of moderate certainty, and evidence that IPTp-meflo-
quine increased drug-related adverse effects (namely, vomiting and
dizziness) compared with IPTp-sulfadoxine-pyrimethamine was
of high and moderate certainty (respectively). We considered the
effects of IPTp-mefloquine in decreasing placental malaria risk
compared with IPTp-sulfadoxine-pyrimethamine to be of low cer-
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tainty because of substantial heterogeneity among trials. Finally,
we considered evidence of no effects of mefloquine compared with
sulfadoxine-pyrimethamine on lowbirthweight and stillbirths and
abortions to be of moderate certainty.
ForHIV-infectedwomen, evidence that cotrimoxazole plus IPTp-
mefloquine was superior to cotrimoxazole in reducing the risk of
maternal peripheral parasitaemia and anaemia at delivery was of
moderate certainty, whereas evidence regarding lack of effect on
risk of placental malaria was of high certainty. Evidence of no ef-
fects of cotrimoxazole plus IPTp-mefloquine compared with cot-
rimoxazole on low birth weight and stillbirths and abortions was
of moderate and very low certainty, respectively, because of serious
risk of bias of one of the included trials and substantial hetero-
geneity. Finally, we considered evidence of mefloquine increasing
risks of vomiting and dizziness to be of low certainty because het-
erogeneity among trials was substantial and the 95% CI was wide.
Potential biases in the review process
It seems unlikely that we have missed any trials examining meflo-
quine for prevention of malaria in pregnant women.
Agreements and disagreements with other
studies or reviews
A previous Cochrane Review on drugs for preventing malaria in
pregnant women in endemic areas analyzed the effects of meflo-
quine for prevention of malaria (Radeva-Petrova 2014). Our re-
sults are consistent with those previously reported but include
more trials and thus may be more robust.
The findings of thisCochraneReview are also consistentwith those
of a previous systematic review assessing the safety and tolerability
of mefloquine in pregnancy (González 2013).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In past decades,many clinical trials have testedmefloquine chemo-
prevention to prevent malaria and its consequences in pregnant
women.
For HIV-uninfected pregnant women, IPTp-mefloquine bet-
ter reduces malaria effects compared with IPTp-sulfadoxine-
pyrimethamine, but the drug is worse tolerated than sulfadoxine-
pyrimethamine. For HIV-infected pregnant women, IPTp-meflo-
quine added to cotrimoxazole prophylaxis reduces the risk of im-
portantmalaria consequences better than cotrimoxazole alone, but
drug tolerability constitutes a health issue.
The data show thatmefloquine is an efficacious and safe antimalar-
ial drug in terms of pregnancy outcomes for prevention of malaria
in pregnancy. However, the high proportion of mefloquine-related
adverse events constitutes an important barrier to its effectiveness
for malaria preventive treatment in pregnant women.
Implications for research
Mefloquine efficacy to prevent malaria effects in pregnancy is well
established. Future research should concentrate on finding a dose
that would provide the same antimalarial beneficial effects while
reducing its drug-related adverse events, especially as weekly pro-
phylaxis (for example, at a dose of 5 mg/kg) for HIV-uninfected
women living in areas of high sulfadoxine-pyrimethamine resis-
tance. Researchers also should further examine findings on the
two-fold increased risk of mother-to-child transmission of HIV
among mefloquine recipients.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Briand 2009 BEN
Methods Trial design: open-label, randomized, 2-arm trial of 2 doses of IPTp
Follow-up: the second IPTp dose was administered from 30 weeks of gestation and at
least 1 month after administration of the first dose. Women were visited at home, at
delivery, and until 6 weeks after the end of pregnancy
Adverse event (AE) monitoring: AEs were recorded via an open-labelled questionnaire
during visits at home occurring within 1 week after each IPTp intake
Participants Numbers of participants randomized: 802 (IPTp-mefloquine), 799 (IPTp-sulfadoxine-
pyrimethamine)
Inclusion criteria: HIV-uninfected women of all gravidities at 16 to 28 weeks of gestation
who had no history of a neurological or psychiatric disorder and who had not previously
used sulfadoxine-pyrimethamine or mefloquine nor reported having adverse reactions
to medications containing sulfa
Exclusion criteria: pregnant women not meeting inclusion criteria
Interventions • Two doses of IPTp with sulfadoxine-pyrimethamine (1500 mg of sulfadoxine and
75 mg of pyrimethamine per dose)
• Two doses of IPTp with mefloquine (15 mg/kg per dose; Mepha)
Outcomes • Maternal peripheral parasitaemia at delivery
• Placental malaria (presence of asexual stage parasites in blood smear)
• Maternal anaemia at delivery (defined by haemoglobin < 10 g/dL)
• Mean haemoglobin at delivery
• Clinical malaria episodes during pregnancy
• Cord blood parasitaemia
• Mean birth weight
• Low birth weight rates
• Prematurity rates
• Spontaneous abortion (expulsion of a foetus at < 28 weeks of gestation) rates
• Stillbirth rates (delivery of a dead child at < 28 weeks of gestation)
• Congenital malformation rates
• Maternal mortality
• Neonatal mortality
• Frequency of adverse events: vomiting, headache, weakness, and dizziness
Notes Country: Benin
Setting: antenatal care clinics from Ouidah,a semi-rural town
Transmission: perennial with seasonal peaks
Resistance: in 2005, rates of sulfadoxine-pyrimethamine and mefloquine resistance in
vivo in children < 5 years of age were estimated to be 50% and 2.5% by day 28 of
treatment, respectively
Dates: 2005 to 2008
Funding: Fonds de Solidarité Prioritaire (French Ministry of Foreign Affairs; project no.
2006-22); Institut de Recherche pour le Développement;
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Fondation pour la Recherche Médicale (grant FDM20060907976 to V.B.); Fondation
de France; and Fondation Mérieux
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Randomization of subjects was
stratified according to maternity clinic and
gravidity”
Allocation concealment (selection bias) High risk Allocation was not concealed.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding was reported, and safety out-
comes are likely to be influenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
Efficacy
Low risk No blinding of outcome assessment was re-
ported, but the review authors judge that
the efficacy outcome measurement is not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
Safety
High risk No blinding of outcome assessment was re-
ported; thus the review authors judge that
the safety outcome measurement is likely
to be influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data were balanced in
numbers across intervention groups, and
similar reasons for missing data were re-
ported across groups
Selective reporting (reporting bias) Low risk The study protocol is not available, but it is
clear that published reports describe all ex-
pected outcomes, including those that were
prespecified
Other bias Low risk The study appears to be free of other
sources of bias.
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Methods Trial design: randomized, open-label trial of 3 doses of IPTp
Follow-up: 3 scheduled IPTp administrations with at least a 1-month interval between
them. IPTp-mefloquine administration and provision of cotrimoxazole. Clinical and
adherence information, complete blood count, CD4 count, malaria screening, and treat-
ment of malaria
At delivery: blood smears from placenta and umbilical cords and evaluation of newborns.
Infant evaluation at 6 weeks, 4 months, and 2 months after weaning
Adverse event (AE)monitoring: self-reporting of all AEs. All adverse events were recorded
at each visit. In addition, direct observation of early adverse reactions to mefloquine
within 30 minutes after supervised intake was noted and later reactions were collected
by phone the same day/evening or on the next day. Medical examination was performed
2 weeks after cotrimoxazole initiation to search for cutaneous reactions. An independent
data and safety monitoring board reviewed all SAEs
Participants Numbers of participants randomized: 146 (cotrimoxazole), 146 (cotrimoxa-
zole+mefloquine)
Inclusion criteria: HIV-infected pregnant women of all gravidities aged > 18 years, living
permanently in the study area, between 16 and 28 weeks of gestation; last dosage of IPTp
taken 1 month before enrolment; women requiring antimalarial treatment enrolled at
least 2 weeks after completion of treatment
Exclusion criteria: history of neuropsychiatric disorder; severe kidney or liver disease;
serious adverse reaction to mefloquine, sulfa drugs, or quinine
Interventions IPTp with mefloquine plus cotrimoxazole
• 15 mg/kg single dose (250 mg tablet, Lariam, Roche), 3 doses 1 month apart
• Daily dose of 800 mg sulfamethoxazole and 160 mg trimethoprim
Cotrimoxazole
• Daily dose of 800 mg sulfamethoxazole and 160 mg trimethoprim
All study participantswere givenLLITNs anddaily supplementationwith 100mg ferrous
sulphate and 5 mg folic acid
The first dose was given at ≥ 16 weeks of gestation.
All women were observed for 30 minutes following IPTp administration. Women vom-
iting within the first 30 minutes were given a second full IPTp dose
Asymptomatic women and women with low parasitaemia (< 1000 parasites/µL) were
treated by the IPTp-mefloquine dose in the mefloquine groups. Otherwise, women
received artemether-lumefantrine or oral quinine. Those with severe malaria were treated
with intravenous quinine
Outcomes • Maternal peripheral parasitaemia at delivery (PCR)
• Placental parasitaemia at delivery (blood smear and PCR)
• Mean maternal haemoglobin at delivery
• Maternal anaemia (< 9.5 g/dL) at delivery
• Cord blood parasitaemia at delivery
• Mean birth weight
• Low birth weight (< 2500 g)
• Prematurity
• Serious adverse events (SAEs) during pregnancy
• Spontaneous abortions (< 28 weeks)
• Stillbirths (≥ 28 weeks of gestation)
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• Congenital malformations (< 28 weeks of gestation)
• Early neonatal mortality (< 7 days)
• Neonatal mortality
• Infant deaths after 7 days
• Vomiting
• Dizziness
• Headache
• Fatigue/weakness
Notes Country: Benin
Setting: 5 urban hospitals with PMTCT programmes
Malaria transmission: intense andperennial transmission,with peaks during rainy seasons
Resistance: increasing risk of resistance to sulfa drugs. Parasite resistance to cotrimoxazole
Dates: 2009 to 2012
Funding: Sidaction Grant AI19-3-01528
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Randomization was stratified ac-
cording to the study site and the number
of previous pregnancies”
Allocation concealment (selection bias) Low risk Quote: “The study coordination center re-
tained the master list and assigned treat-
ment by phone”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The trial blinded only the microscopist
who evaluated blood smears
Blinding of outcome assessment (detection
bias)
Efficacy
Low risk No blinding of outcome assessment was re-
ported, but the review authors judge that
the efficacy outcome measurement is not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
Safety
High risk No blinding of outcome assessment was re-
ported; thus the review authors judge that
the safety outcome measurement is likely
to be influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data were balanced in
numbers across groups.
Selective reporting (reporting bias) Low risk Protocol was not available, but published
report describes all expected outcomes in-
cluding those prespecified
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Other bias Low risk The study appears to be free of other
sources of bias.
Denoeud-Ndam 2014b BEN
Methods Trial design: randomized, open-label trial of 3 doses of IPTp
Follow-up: 3 scheduled IPTp administrations with at least a 1-month interval between
them. IPTp-mefloquine administration and provision of cotrimoxazole. Clinical and
adherence information, complete blood count, CD4 count, malaria screening, and treat-
ment of malaria
At delivery: blood smears from placenta and umbilical cords and evaluation of newborns.
Infant evaluation at 6 weeks, 4 months, and 2 months after weaning
Adverse event (AE)monitoring: self-reporting of all AEs. All adverse events were recorded
at each visit. In addition, direct observation of early adverse reactions to mefloquine
within 30 minutes after supervised intake was noted and later reactions were collected
by phone the same day/evening or on the next day. Medical examination was performed
2 weeks after cotrimoxazole initiation to search for cutaneous reactions. An independent
data and safety monitoring board reviewed all SAEs
Participants Numbers of participants randomized: 72 (cotrimoxazole), 68 (mefloquine)
Inclusion criteria: HIV-infected pregnant women of all gravidities aged > 18 years, living
permanently in the study area, between 16 and 28 weeks of gestation, last dosage of IPTp
taken 1 month before enrolment, women requiring antimalarial treatment enrolled at
least 2 weeks after completion of treatment
Exclusion criteria: history of neuropsychiatric disorder; severe kidney or liver disease;
serious adverse reaction to mefloquine, sulfa drugs, or quinine
Interventions IPTp with mefloquine
• 15 mg/kg single dose (250 mg tablet, Lariam, Roche)
• Three doses 1 month apart
Cotrimoxazole
• Daily dose of 800 mg sulfamethoxazole and 160 mg trimethoprim
All study participantswere givenLLITNs anddaily supplementationwith 100mg ferrous
sulphate and 5 mg folic acid
The first dose was given at ≥ 16 weeks of gestation.
All women were observed for 30 minutes following IPTp administration. Women vom-
iting within the first 30 minutes were given a second full IPTp dose
Asymptomatic women and women with low parasitaemia (< 1000 parasites/µL) in the
mefloquine groups were treated by the IPTp-mefloquine dose. Otherwise, women re-
ceived artemether-lumefantrine or oral quinine. Thos with severe malaria were treated
with intravenous quinine
Outcomes • Maternal peripheral parasitaemia at delivery (PCR)
• Placental parasitaemia at delivery (blood smear and PCR)
• Mean maternal haemoglobin at delivery
• Maternal anaemia (< 9.5 g/dL) at delivery
• Cord blood parasitaemia at delivery
• Mean birth weight
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• Low birth weight (< 2500 g)
• Prematurity
• Serious adverse events (SAEs) during pregnancy
• Spontaneous abortions (< 28 weeks)
• Stillbirths (≥ 28 weeks of gestation)
• Congenital malformations (< 28 weeks of gestation)
• Early neonatal mortality (< 7 days)
• Neonatal mortality
• Infant deaths after 7 days
• Vomiting
• Dizziness
• Headache
• Fatigue/weakness
Notes Country: Benin
Setting: 5 urban hospitals with PMTCT programmes
Malaria transmission: intense andperennial transmission,with peaks during rainy seasons
Resistance: increasing risk of resistance to sulfa drugs. Parasite resistance to cotrimoxazole
Dates: 2009 to 2012
Funding: Sidaction Grant AI19-3-01528
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Randomization was stratified ac-
cording to the study site and the number
of previous pregnancies”
Allocation concealment (selection bias) Low risk Quote: “The study coordination center re-
tained the master list and assigned treat-
ment by phone”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The trial blinded only the microscopist
who evaluated blood smears
Blinding of outcome assessment (detection
bias)
Efficacy
Low risk No blinding of outcome assessment was re-
ported, but the review authors judge that
the efficacy outcome measurement is not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
Safety
High risk No blinding of outcome assessment was re-
ported; thus the review authors judge that
the safety outcome measurement is likely
to be influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data were balanced in
numbers across groups.
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Selective reporting (reporting bias) Low risk Protocol was not available, but published
report describes all expected outcomes in-
cluding those prespecified
Other bias Low risk The study appears to be free of other
sources of bias.
Gonzalez 2014a BEN GAB MOZ TAN
Methods Trial design: open-label, randomized, 3-arm trial of 2 doses of IPTp
Follow-up: at each scheduled and unscheduled visit, a standardized symptom question-
naire was completed, as were blood smears for malaria parasites, and haemoglobin if
symptoms and/or signs were suggestive of malaria. At delivery, blood samples were col-
lected for haematological and parasitological evaluation. Weighting of newborns and
gestational age at birth were recorded. Malaria parasite was determined 6 weeks after the
end of pregnancy
Adverse event monitoring: home visits by field workers were done 2 days after IPTp
administration to assess drug tolerability
Solicited and unsolicited adverse events (AEs) were assessed. The former were assessed by
directed questioning regarding malaria-related signs and symptoms during unscheduled
visits, whereas the latter were assessed through open questioning during scheduled visits
Participants Numbers of participants randomized: 1578 (sulfadoxine-pyrimethamine), 1580 (meflo-
quine full dose), 1591 (mefloquine split)
Inclusion criteria: HIV-uninfected women of all gravidities attending the antenatal care
clinic for the first time, did not receive IPTp during current pregnancy, permanent
residence in the study area, gestational age of ≤ 28 weeks
Exclusion criteria: HIV-positive; history of allergy to sulfa drugs or mefloquine; history
of severe renal, hepatic, psychiatric, or neurological disease; mefloquine or halofantrine
treatment in the preceding 4 weeks; participating in other intervention studies
Interventions IPTp with sulfadoxine-pyrimethamine, 3 tablets
• 500 mg/25 mg
• Two doses 1 month apart
IPTp with mefloquine
• 15 mg/kg given once as a full dose (250-mg tablets)
• Two doses 1 month apart
IPTp with mefloquine (split dose)
• 15 mg/kg given as a split dose over 2 days (250-mg tablets)
• Two doses 1 month apart
All study participants were given LLITNs.
The first dose was given at > 13 weeks of gestation.
All women were observed for 60 minutes following IPT administration. Women vom-
iting within the first 30 minutes were given a second full IPT dose, and those vomiting
30 to 60 minutes after drug intake were given a half replacement dose
Uncomplicated malaria episodes were treated with oral quinine (first trimester) or
artemether-lumefantrine (second and third trimesters); severe malaria episodes were
treated with parenteral quinine
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Outcomes • Maternal peripheral parasitaemia at delivery
• Placental parasitaemia at delivery
• Mean maternal haemoglobin at delivery
• Maternal anaemia (< 10 g/dL) at delivery
• Clinical malaria episodes during pregnancy
• Cord blood parasitaemia at delivery
• Cord blood anaemia
• Mean birth weight
• Low birth weight (< 2500 g)
• Low birth weight by gravidity
• Prematurity
• Malaria in first year of life
• Hospital admissions in first year of life
• Malaria in first year of life (infant morbidity)
• Hospital admissions in first year of life (infant morbidity)
• Serious adverse events (SAEs) during pregnancy
• Spontaneous abortions (< 20 complete weeks of gestation)
• Stillbirths (> 20 complete weeks of gestation)
• Congenital malformations
• Maternal mortality
• Neonatal mortality
• Infant mortality
• Vomiting
• Headache
• Fatigue/weakness
• Dizziness
Notes Country: Tanzania, Mozambique, Benin, and Gabon
Setting: antenatal care clinics
Transmission: mesoendemic in Tanzania and Mozambique, hyperendemic in Benin and
Gabon
Resistance: resistance to sulfadoxine-pyrimethamine due to long-term sulfadoxine-
pyrimethamine for IPTp
Dates: 2009 to 2013
Funding: this study was funded by the European Developing Countries Clinical Trials
Partnership (EDCTP; IP.2007.31080.002), the Malaria in Pregnancy Consortium, and
the Instituto de Salud Carlos III (PI08/0564), in Spain. RG and MR were partially
supported by grants from the Spanish Ministry of Health (ref. CM07/0015 and CM11/
00278, respectively). The CISM receives core funding from the Spanish Agency for
International Cooperation (AECID). LLITNs (Permanet) were donated by Vestergaard
Frandsen
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The allocation of the participants
to the study armswas done centrally by ran-
domization stratified by country accord-
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ing to a 1:1:1 scheme. The sponsor’s in-
stitution biostatistician produced the com-
puter-generated randomization list for each
recruiting site”
Allocation concealment (selection bias) Low risk Quote: “Treatment allocation for each par-
ticipant was concealed in opaque sealed en-
velopes that were opened only after recruit-
ment. Study participants were assigned a
unique study number linked to the allo-
cated treatment group”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The study was designed as an
open-label, randomized, three-arm trial to
compare two-dose mefloquine with two-
dose SP for IPTp”
Blinding of outcome assessment (detection
bias)
Efficacy
Low risk No blinding of outcome assessment was re-
ported, but the review authors judge that
the efficacy outcome measurement is not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
Safety
High risk No blinding of outcome assessment was re-
ported; thus the review authors judge that
the safety outcome measurement is likely
to be influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk All excluded participants, at any stage of
the trial, are counted in the flow chart
(both ITT and ATP cohorts). Missing out-
come data were balanced in numbers across
groups
Selective reporting (reporting bias) Low risk Not observed. Protocol available
Other bias Low risk The study appears to be free of other
sources of bias.
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Methods Trial design: individually randomized, double-blind, placebo-controlled trial of 3 doses
of IPTp
Follow-up: at each scheduled and unscheduled visit, a standardized symptom question-
naire was completed, as were blood smears for malaria parasites, and haemoglobin if
symptoms and/or signs were suggestive of malaria. On a monthly basis, adherence to
cotrimoxazole and LLITN was assessed. At delivery, blood samples were collected for
haematological and parasitological evaluation with CD4 cell count and HIV viral load.
Weighting of newborns and gestational age at birth were recorded. Malaria parasite was
determined 6 weeks after the end of pregnancy
Adverse event monitoring: home visits by field workers were done 2 days after IPTp
administration to assess drug tolerability
Solicited and unsolicited adverse events (AEs) were assessed. The former were assessed by
directed questioning of malaria-related signs and symptoms during unscheduled visits,
whereas the latter were assessed through open questioning during scheduled visits
Participants Numbers of participants randomized: 537 (placebo+cotrimoxazole), 534 (meflo-
quine+cotrimoxazole)
Inclusion criteria: HIV-infected women of all gravidities attending the antenatal care
clinic for the first time, did not receive IPTp during current pregnancy, permanent
residence in the study area, gestational age of ≤ 28 weeks, HIV positive
Exclusion criteria: history of allergy to sulfa drugs or mefloquine; history of severe renal,
hepatic, psychiatric, or neurological disease; mefloquine or halofantrine treatment in the
preceding 4 weeks; participating in other intervention studies
Interventions IPTp with mefloquine
• 15 mg/kg single dose (maximum dosage would not exceed 1500 mg of
mefloquine)
• Three doses 1 month apart
IPTp with placebo
• Identical to mefloquine tablets in shape and colour
• Three doses 1 month apart
All study participants had monthly cotrimoxazole prophylaxis (fixed combination 800
mg of trimethroprim and 160 mg of sulfamethoxazole/tablet)
All study participants were given LLITNs.
The first dose was given at > 13 weeks of gestation.
All women were observed for 60 minutes following IPT administration. Women vomit-
ing within the first 30 minutes were given a second full IPTp dose, and those vomiting
30 to 60 minutes after drug intake were given a half replacement dose
Uncomplicated malaria episodes were treated with oral quinine (first trimester) or
artemether-lumefantrine (second and third trimesters); severe malaria episodes were
treated with parenteral quinine
Outcomes • Maternal peripheral parasitaemia at delivery (PCR)
• Placental parasitaemia at delivery (blood smear and PCR)
• Mean maternal haemoglobin at delivery
• Maternal anaemia (< 9.5 g/dL) at delivery
• Clinical malaria episodes during pregnancy
• Cord blood parasitaemia at delivery
• Mean birth weight
• Low birth weight (< 2500 g)
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• Prematurity
• Serious adverse events (SAEs) during pregnancy
• Spontaneous abortions (< 20 complete weeks of gestation)
• Stillbirths (> 20 weeks of gestation)
• Congenital malformations
• Maternal mortality
• Perinatal mortality
• Early neonatal mortality (< 7 days)
• Neonatal mortality
• Vomiting
• Headache
• Fatigue/weakness
• Dizziness
Notes Countries: Tanzania, Mozambique, and Kenya
Setting: antenatal care clinics
Transmission: mesoendemic in Tanzania and Mozambique, holoendemic in Kenya
Resistance: resistance to sulfadoxine-pyrimethamine due to long-term sulfadoxine-
pyrimethamine for IPTp
Dates: 2010 to 2013
Funding: this study was funded by the European Developing Countries Clinical Trials
Partnership (EDCTP; IP.2007.31080.002), the Malaria in Pregnancy Consortium, and
the Instituto de Salud Carlos III (PI08/0564), in Spain. RG and MR were partially
supported by grants from the Spanish Ministry of Health (ref. CM07/0015 and CM11/
00278, respectively). The CISM receives core funding from the Spanish Agency for
international Cooperation (AECID). LLITNs (Permanet) were donated by Vestergaard
Frandsen, and cotrimoxazole tablets (Septrin) by UCB Pharma, in Spain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The allocation of the participants
to the study arms was done centrally by
block randomization (block size of 6) strat-
ified by country”
Allocation concealment (selection bias) Low risk Quote: “The Pharmacy Department of the
Hospital Clinic in Barcelona produced and
safeguarded the computer-generated ran-
domization list for each recruiting site un-
til unblinding, and carried out the mask-
ing, labelling, and packaging of all study
interventional drugs. Study number alloca-
tion for each participant was concealed in
opaque sealed envelopes that were sequen-
tially numbered and opened only after re-
cruitment by study health personnel”
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Study participants were assigned a
unique study
number linked to the allocated treatment
group. Investigators, laboratory staff, care
providers, and study participants were
blinded to intervention throughout the
study”
Placebo tablets were identical to meflo-
quine tables in shape and colour
Blinding of outcome assessment (detection
bias)
Efficacy
Low risk Quote: “Investigators, laboratory staff, care
providers, and study participants were
blinded to intervention throughout the
study”
Blinding of outcome assessment (detection
bias)
Safety
Low risk Quote: “Investigators, laboratory staff, care
providers, and study participants were
blinded to intervention throughout the
study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All excluded participants, at any stage of
the trial, are counted in the flow chart
(both ITT and ATP cohorts). Missing out-
come data were balanced in numbers across
groups
Selective reporting (reporting bias) Low risk Not observed. Protocol available
Other bias Low risk The study appears to be free of other
sources of bias.
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Methods Trial design: double-blind, placebo-controlled trial. Phase 1 and phase 2
Follow-up: in both phases, weekly visits included assessment of weight, temperature,
pulse, blood pressure, fundal height, presence of oedema and anaemia, a symptom
questionnaire on gastrointestinal and central nervous system side effects, malaria blood
smear, electrocardiogram, and haematology and biochemistry every 2 weeks. Treatment
of malaria and anaemia and food supply were provided when needed. At phase 2, ex-
panded questionnaires and Romberg test were used. At delivery, measurement of new-
born weight, details of labour, cord and maternal blood samples (malaria and anaemia)
, and placental biopsy were included. At phase 2, autopsy of death was performed in
newborns. Follow-up consisted of different measurements in children until 2 years of
age (weight, height, head and arm circumferences) and determination of age when baby
could first crawl, sit, walk, and talk. At phase 2, age at first symptomatic malaria, malaria
blood smear, haematocrit, and full clinical examination were performed
Adverse event monitoring: weekly symptom questionnaire focusing on gastrointestinal,
neurological, dermatological, and systemic symptoms
Participants Numbers of participants randomized: 170 (mefloquine - 60 phase 1, 110 phase 2), 169
(placebo - 59 phase 1, 110 phase 2)
Inclusion criteria: women of all gravidities and unknown HIV status (not tested) who
attended the ANC clinic and were at > 20 weeks of estimated gestation
Exclusion criteria: women not meeting inclusion criteria.
Interventions IPTp with mefloquine
• Phase 1: 500 mg of base loading dose followed by 250 mg weekly for 4 weeks and
thereafter 125 mg weekly until delivery
• Phase 2: 250 mg of base weekly given for 4 weeks followed by 125 mg weekly
until delivery
IPTp with placebo
• Identical to mefloquine tablets (weekly dosage)
The first dose was given at > 20 weeks of gestation.
Anaemia was treated with ferrous sulphate and folic acid. Uncomplicated Plasmodium
falciparummalaria was treated with quinine sulphate, P vivaxwith chloroquine sulphate,
and severe malaria with intravenous quinine dihydrochloride
Outcomes • Maternal peripheral parasitaemia during pregnancy
• Placental malaria
• Mean birth weight
• Low birth weight
• Prematurity
• Stillbirths
• Spontaneous abortions
• Congenital malformations
• Maternal mortality
• Infant mortality
Notes Country: Thailand
Setting: 3 camps for displaced people: phase 1 antenatal clinics, phase 2 hospital
Dates: 1987 to 1990
Transmission: seasonal malaria transmission (mesoendemic)
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Resistance: resistances to mefloquine, quinine, chloroquine, and antifolates
Funding: United Nations Development Programme/World Bank/World Health Orga-
nization Special Programme for Research and Training in Tropical Diseases; Wellcome
Trust of Great Britain; Prevention Fundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Women were randomized to receive meflo-
quine or placebo. Not well explained how
women were randomized
Allocation concealment (selection bias) Unclear risk Not explained
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind trial
Quote: “The investigators were unaware of
the randomization”
Placebo tablets were identical to meflo-
quine tablets.
Blinding of outcome assessment (detection
bias)
Efficacy
Unclear risk Not explained
Blinding of outcome assessment (detection
bias)
Safety
Unclear risk Not explained
Incomplete outcome data (attrition bias)
All outcomes
Low risk All excluded participants and those who
decided to drop out are correctly reported
along with reasons. Missing outcome data
were balanced in numbers across groups
Selective reporting (reporting bias) Unclear risk Results of cord and maternal blood smears
are not shown (published elsewhere?). No
protocol is available. Nothing else was ob-
served
Other bias Low risk The study appears to be free of other
sources of bias.
Abbreviations: AE: adverse event; AECID: Spanish Agency for International Cooperation; ANC: antenatal care; ATP: adenosine
triphosphate; CISM: Centro de Investigação em Saúde da Manhiça; IPTp: intermittent preventive treatment for malaria in preg-
nancy; IPTp-mefloquine: intermittent preventive mefloquine treatment in pregnancy; IPTp-sulfadoxine-pyrimethamine: intermit-
tent preventive sulfadoxine-pyrimethamine treatment in pregnancy; ITT: intention-to-treat; LLITN: long-lasting insecticide-treated
net; PCR: polymerase chain reaction; PMTCT: prevention of mother-to-child transmission; SAE: serious adverse event.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Balocco 1992 Letter to editor reporting on the results of pregnancy of 24 women exposed tomefloquine in early pregnancy.
The report was excluded because it did not meet the inclusion criteria
Briand 2015 This publication reports the findings of a re-analysis of previous published data comparing mefloquine with
sulphadoxine-pyrimethamine for IPTp in Benin using a multiple outcome approach, which allowed the
joint assessment of efficacy and tolerability. This analysis was not included in the review because the original
study (Briand 2009 BEN) was already included and it did not add additional data
Denoeud-Ndam 2012 Study comparing mefloquine tolerability as IPTp between HIV-infected and uninfected women participat-
ing in three included trials from Benin (Briand 2009 BEN and Denoeud-Ndam 2014a and b). This analysis
was excluded from the review because it did not provide additional data from already included trials
Nosten 1990 THA The studywas designed as a dose-finding pharmacokinetic study in 20 pregnant women in the third trimester
of pregnancy who received mefloquine as prophylaxis. The trial did not compare the safety and efficacy of
mefloquine with another antimalarial drug and thus, it did not meet inclusion criteria
Phillips-Howard 1998 Publication reporting on a data analysis of reported use of mefloquine during the 1st trimester of pregnancy
in European travellers. This analysis was excluded from the review because it did not meet inclusion criteria
Schlagenhauf 2012 This publication presents the analysis of the reports of exposure to mefloquine in pregnancy received by the
Roche post-marketing surveillance system. This analysis was excluded from the review because it did not
meet inclusion criteria
Smoak 1997 This publication reports a case series of 72 US soldiers who inadvertently took mefloquine during pregnancy
for prophylaxis. This publication was excluded from the review because it did not meet inclusion criteria
Steketee 1996 MAL We were not convinced that allocation was unbiased.
Quote: “The assignment of regimens was based on the clinic day of enrolment. All women making their
first antenatal clinic visit on a given day were assigned to the same regimen; the following clinic day, enrolled
women were assigned a different regimen”
We noted bias in allocation supported by statistically and clinically significant differences between interven-
tion groups (3 groups under different chloroquine regimens versus 1 group under mefloquine regimen)
Vanhauwere 1998 Study evaluating 1627 reports of mefloquine exposure pregnancy, mainly for chemoprophylaxis received by
the Roche Post-marketing surveillance system between 1986 and 1996.This analysis was excluded from the
review because it did not meet inclusion criteria
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Characteristics of ongoing studies [ordered by study ID]
Akinyotu 2015 NIG
Trial name or title A comparative study of mefloquine and SP as prophylaxis against malaria in pregnant HIV-infected patients
Methods Allocation: randomized
Intervention model: parallel assignment
Masking: single-blind (outcomes assessor)
Primary purpose: prevention
Participants Inclusion criteria:
• Pregnant HIV-infected patients
• Gestational age ≥ 16 weeks
• No history of use of mefloquine or sulphadoxine
• Pyrimethamine 4 weeks before recruitment
Exclusion criteria:
• Anaemia packed cell volume < 30%
• Pre-existing medical conditions - diabetes mellitus, hypertension
• Allergy to sulphadoxine-pyrimethamine or mefloquine
• Non-consenting patients
• Multiple gestation
• Known psychiatric illness
• Known seizure disorder
• History of severe renal or hepatic disease
Interventions • Mefloquine: 250 mg 3 doses 4 weeks apart
• Sulfadoxine-pyrimethamine: 500 mg sulphadoxine and 25 mg pyrimethamine, 3 tablets 4 weeks apart
for 3 doses
Outcomes No information available
Starting date September 2015
Contact information Oriyomi O Akinyotu, MBBS; Ibadan: +2348035044590; oriyomiddoc@yahoo.com
Notes We contacted the study authors, but they could not provide the data to us because the study was part of a
thesis not yet defended
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D A T A A N D A N A L Y S E S
Comparison 1. Mefloquine versus sulfadoxine-pyrimethamine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical malaria episodes during
pregnancy
2 Rate Ratio (Fixed, 95% CI) 0.83 [0.65, 1.05]
2 Maternal peripheral parasitaemia
at delivery
2 5455 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.48, 0.86]
3 Placental malaria 2 4668 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.58, 1.86]
4 Mean haemoglobin at delivery 2 5588 Mean Difference (IV, Fixed, 95% CI) 0.10 [0.01, 0.19]
5 Maternal anaemia at delivery 2 5469 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.76, 0.94]
6 Severe maternal anaemia at
delivery
2 5469 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.58, 1.48]
7 Cord blood parasitaemia 2 5309 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.13, 1.46]
8 Cord blood anaemia 1 4006 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.87, 1.23]
9 Mean birth weight 2 5241 Mean Difference (IV, Fixed, 95% CI) 2.52 [-25.66, 30.69]
10 Low birth weight 2 5641 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.78, 1.17]
11 Low birth weight by gravidity 2 5641 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.84, 1.13]
11.1 Primigravidae 2 1576 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.80, 1.30]
11.2 Multigravidae 2 4065 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.78, 1.14]
12 Prematurity 2 4640 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.76, 1.40]
13 Malaria in first year of life 1 Rate Ratio (Fixed, 95% CI) 0.97 [0.82, 1.15]
14 Hospital admissions in first
year of life
1 Rate Ratio (Fixed, 95% CI) 0.93 [0.75, 1.17]
15 SAEs during pregnancy 1 4674 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.81, 1.20]
16 Stillbirths and abortions 2 6219 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.91, 1.58]
17 Congenital malformations 2 5931 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.51, 2.37]
18 Maternal mortality 2 6219 Risk Ratio (M-H, Random, 95% CI) 2.41 [0.27, 21.23]
19 Neonatal mortality 2 6134 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.67, 1.43]
20 Infant mortality 1 Rate Ratio (Fixed, 95% CI) 1.00 [0.66, 1.52]
21 AEs: vomiting 2 6272 Risk Ratio (M-H, Fixed, 95% CI) 4.76 [4.13, 5.49]
22 AEs: fatigue/weakness 2 6272 Risk Ratio (M-H, Random, 95% CI) 4.62 [1.80, 11.85]
23 AEs: dizziness 2 6272 Risk Ratio (M-H, Random, 95% CI) 4.21 [3.36, 5.27]
24 AEs: headache 2 6272 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.25, 1.94]
Comparison 2. Mefloquine plus cotrimoxazole versus cotrimoxazole
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical malaria episodes during
pregnancy
1 Rate Ratio (Fixed, 95% CI) 0.76 [0.33, 1.76]
2 Maternal peripheral parasitaemia
at delivery (PCR)
2 989 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.30, 0.93]
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3 Placental malaria (blood smear) 2 1144 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.29, 0.89]
4 Placental malaria (PCR) 2 977 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.14, 0.57]
5 Mean haemoglobin at delivery 2 1167 Mean Difference (IV, Random, 95% CI) 0.07 [-0.32, 0.46]
6 Maternal anaemia at delivery (<
9.5 g/dL)
2 1197 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.73, 1.20]
7 Maternal severe anaemia at
delivery
2 1167 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.41, 2.08]
8 Cord blood parasitaemia 2 1166 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.03, 3.13]
9 Mean birth weight 2 1220 Mean Difference (IV, Random, 95% CI) -25.75 [-86.99, 35.
49]
10 Low birth weight 2 1220 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.89, 1.60]
11 Prematurity 2 824 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.58, 1.96]
12 SAEs during pregnancy 2 1347 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.50, 0.95]
13 Spontaneous abortions and
stillbirths
2 1347 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.42, 2.98]
14 Congenital malformations 2 1312 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.22, 1.67]
15 Maternal mortality 2 1347 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.13, 2.01]
16 Neonatal mortality 2 1239 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.65, 2.69]
17 Mother-to-child transmission
HIV
2 1019 Risk Ratio (M-H, Fixed, 95% CI) 1.92 [1.13, 3.25]
18 AEs: vomiting 2 1347 Risk Ratio (M-H, Random, 95% CI) 20.88 [1.40, 311.66]
19 AEs: fatigue/weakness 2 1347 Risk Ratio (M-H, Random, 95% CI) 2.95 [0.26, 32.93]
20 AEs: dizziness 2 1347 Risk Ratio (M-H, Random, 95% CI) 16.34 [0.39, 684.99]
21 AEs: headache 2 1347 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.28, 2.10]
Comparison 3. Mefloquine versus cotrimoxazole
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal peripheral parasitaemia
at delivery (PCR)
1 98 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.03, 1.72]
2 Placental malaria (PCR) 1 94 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.13, 4.15]
3 Placental malaria (blood smear) 1 108 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.01, 8.30]
4 Mean haemoglobin at delivery 1 100 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.67, 0.47]
5 Maternal anaemia at delivery (<
9.5 g/dL)
1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.26, 3.16]
6 Mean birth weight 1 120 Mean Difference (IV, Fixed, 95% CI) -102.0 [-255.52, 51.
52]
7 Low birth weight 1 120 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [0.56, 4.13]
8 Prematurity 1 125 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.33, 3.56]
9 SAEs during pregnancy 1 140 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.28, 4.07]
10 Stillbirths 1 139 Risk Ratio (M-H, Fixed, 95% CI) 4.30 [0.49, 37.49]
11 Spontaneous abortions 1 139 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.07, 16.84]
12 Congenital malformations 1 139 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.16, 7.41]
13 Maternal mortality 1 139 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Neonatal mortality 1 129 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.07, 16.39]
15 Infant deaths after 7 days 1 129 Risk Ratio (M-H, Fixed, 95% CI) 2.10 [0.19, 22.54]
16 AEs: vomiting 1 139 Risk Ratio (M-H, Fixed, 95% CI) 13.43 [3.31, 54.54]
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17 AEs: fatigue/weakness 1 139 Risk Ratio (M-H, Fixed, 95% CI) 6.99 [1.64, 29.81]
18 AEs: dizziness 1 139 Risk Ratio (M-H, Fixed, 95% CI) 52.60 [3.26, 848.24]
19 AEs: headache 1 139 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.39]
Comparison 4. Mefloquine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal peripheral parasitaemia
during pregnancy
1 339 Risk Ratio (M-H, Fixed, 95% CI) 0.13 [0.05, 0.33]
2 Placental malaria 1 220 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.68]
3 Mean birth weight 1 290 Mean Difference (IV, Fixed, 95% CI) -80.0 [-184.65, 24.
65]
4 Low birth weight 1 290 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [0.78, 2.48]
5 Prematurity 1 199 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.15, 1.53]
6 Stillbirths 1 311 Risk Ratio (M-H, Fixed, 95% CI) 2.63 [0.86, 8.08]
7 Spontaneous abortions 1 311 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.04, 5.22]
8 Congenital malformations 1 311 Risk Ratio (M-H, Fixed, 95% CI) 3.82 [0.43, 33.83]
9 Maternal mortality 1 339 Risk Ratio (M-H, Fixed, 95% CI) 2.95 [0.12, 71.85]
10 Infant mortality 1 288 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.63, 1.74]
Analysis 1.1. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 1 Clinical malaria
episodes during pregnancy.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 1 Clinical malaria episodes during pregnancy
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Briand 2009 BEN -0.42 (0.42) 8.7 % 0.66 [ 0.29, 1.50 ]
Gonzalez 2014a BEN GAB MOZ TAN -0.17 (0.13) 91.3 % 0.84 [ 0.65, 1.09 ]
Total (95% CI) 100.0 % 0.83 [ 0.65, 1.05 ]
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.54 (P = 0.12)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours mefloquine Favours sulfadoxine-pyrimethamine
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Analysis 1.2. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 2 Maternal peripheral
parasitaemia at delivery.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 2 Maternal peripheral parasitaemia at delivery
Study or subgroup Mefloquine
Sulfadoxine-
pyrimethamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Briand 2009 BEN 11/675 24/671 22.3 % 0.46 [ 0.22, 0.92 ]
Gonzalez 2014a BEN GAB MOZ TAN 88/2737 63/1372 77.7 % 0.70 [ 0.51, 0.96 ]
Total (95% CI) 3412 2043 100.0 % 0.65 [ 0.48, 0.86 ]
Total events: 99 (Mefloquine), 87 (Sulfadoxine-pyrimethamine)
Heterogeneity: Chi2 = 1.19, df = 1 (P = 0.28); I2 =16%
Test for overall effect: Z = 2.97 (P = 0.0030)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours mefloquine Favours sulfadoxine-pyrimethamine
Analysis 1.3. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 3 Placental malaria.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 3 Placental malaria
Study or subgroup Mefloquine
Sulfadoxine-
pyrimethamine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Briand 2009 BEN 11/163 29/656 37.3 % 1.53 [ 0.78, 2.99 ]
Gonzalez 2014a BEN GAB MOZ TAN 119/2568 72/1281 62.7 % 0.82 [ 0.62, 1.10 ]
Total (95% CI) 2731 1937 100.0 % 1.04 [ 0.58, 1.86 ]
Total events: 130 (Mefloquine), 101 (Sulfadoxine-pyrimethamine)
Heterogeneity: Tau2 = 0.12; Chi2 = 2.74, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours mefloquine Favours sulfadoxine-pyrimethamine
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Analysis 1.4. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 4 Mean haemoglobin
at delivery.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 4 Mean haemoglobin at delivery
Study or subgroup Mefloquine
Sulfadoxine-
pyrimethamine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Briand 2009 BEN (1) 735 11.4 (1.63) 730 11.3 (1.62) 27.1 % 0.10 [ -0.07, 0.27 ]
Gonzalez 2014a BEN GAB MOZ TAN 2743 11.1 (1.5) 1380 11 (1.6) 72.9 % 0.10 [ 0.00, 0.20 ]
Total (95% CI) 3478 2110 100.0 % 0.10 [ 0.01, 0.19 ]
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 2.26 (P = 0.024)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours mefloquine Favours sulfadoxine-pyrimethamine
(1) Denominators based on low birth weight outcome
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Analysis 1.5. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 5 Maternal anaemia
at delivery.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 5 Maternal anaemia at delivery
Study or subgroup Mefloquine
Sulfadoxine-
pyrimethamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Briand 2009 BEN (1) 103/626 129/640 23.2 % 0.82 [ 0.65, 1.03 ]
Gonzalez 2014a BEN GAB MOZ TAN (2) 541/2804 317/1399 76.8 % 0.85 [ 0.75, 0.96 ]
Total (95% CI) 3430 2039 100.0 % 0.84 [ 0.76, 0.94 ]
Total events: 644 (Mefloquine), 446 (Sulfadoxine-pyrimethamine)
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 3.07 (P = 0.0022)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours mefloquine Favours sulfadoxine-pyrimethamine
(1) Anemia at delivery was defined as haemoglobin <10g/dl.
(2) Unpublished data. These were obtained by contacting the authors. In the original paper anaemia was defined as haemoglobin<11g/dl.
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Analysis 1.6. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 6 Severe maternal
anaemia at delivery.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 6 Severe maternal anaemia at delivery
Study or subgroup Mefloquine
Sulfadoxine-
pyrimethamine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Briand 2009 BEN 19/626 15/640 34.1 % 1.29 [ 0.66, 2.53 ]
Gonzalez 2014a BEN GAB MOZ TAN (1) 72/2804 46/1399 65.9 % 0.78 [ 0.54, 1.12 ]
Total (95% CI) 3430 2039 100.0 % 0.93 [ 0.58, 1.48 ]
Total events: 91 (Mefloquine), 61 (Sulfadoxine-pyrimethamine)
Heterogeneity: Tau2 = 0.05; Chi2 = 1.70, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 0.31 (P = 0.75)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours mefloquine Favours sulfadoxine-pyrimethamine
(1) Unpublished data. These were obtained by contacting the authors. In the original paper severe anaemia was defined as haemoglobin<7g/dl.
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Analysis 1.7. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 7 Cord blood
parasitaemia.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 7 Cord blood parasitaemia
Study or subgroup Mefloquine
Sulfadoxine-
pyrimethamine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Briand 2009 BEN 2/653 9/652 43.7 % 0.22 [ 0.05, 1.02 ]
Gonzalez 2014a BEN GAB MOZ TAN 6/2667 4/1337 56.3 % 0.75 [ 0.21, 2.66 ]
Total (95% CI) 3320 1989 100.0 % 0.44 [ 0.13, 1.46 ]
Total events: 8 (Mefloquine), 13 (Sulfadoxine-pyrimethamine)
Heterogeneity: Tau2 = 0.25; Chi2 = 1.49, df = 1 (P = 0.22); I2 =33%
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours mefloquine Favours sulfadoxine-pyrimethamine
Analysis 1.8. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 8 Cord blood anaemia.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 8 Cord blood anaemia
Study or subgroup Mefloquine
Sulfadoxine-
pyrimethamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gonzalez 2014a BEN GAB MOZ TAN 353/2672 170/1334 100.0 % 1.04 [ 0.87, 1.23 ]
Total (95% CI) 2672 1334 100.0 % 1.04 [ 0.87, 1.23 ]
Total events: 353 (Mefloquine), 170 (Sulfadoxine-pyrimethamine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours mefloquine Favours sulfadoxine-pyrimethamine
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Analysis 1.9. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 9 Mean birth weight.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 9 Mean birth weight
Study or subgroup Mefloquine
Sulfadoxine-
pyrimethamine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Briand 2009 BEN (1) 535 3036 (418) 530 3018 (439) 29.9 % 18.00 [ -33.49, 69.49 ]
Gonzalez 2014a BEN GAB MOZ TAN 2778 2997.4 (535.5) 1398 3001.5 (517.8) 70.1 % -4.10 [ -37.76, 29.56 ]
Total (95% CI) 3313 1928 100.0 % 2.52 [ -25.66, 30.69 ]
Heterogeneity: Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours mefloquine Favours sulfadoxine-pyrimethamine
(1) Denominators based on low birth weight outcome
54Mefloquine for preventing malaria in pregnant women (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 1.10. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 10 Low birth weight.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 10 Low birth weight
Study or subgroup Mefloquine
Sulfadoxine-
pyrimethamine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Briand 2009 BEN 59/735 72/730 30.3 % 0.81 [ 0.59, 1.13 ]
Gonzalez 2014a BEN GAB MOZ TAN 360/2778 177/1398 69.7 % 1.02 [ 0.87, 1.21 ]
Total (95% CI) 3513 2128 100.0 % 0.95 [ 0.78, 1.17 ]
Total events: 419 (Mefloquine), 249 (Sulfadoxine-pyrimethamine)
Heterogeneity: Tau2 = 0.01; Chi2 = 1.48, df = 1 (P = 0.22); I2 =33%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours mefloquine Favours sulfadoxine-pyrimethamine
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Analysis 1.11. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 11 Low birth weight
by gravidity.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 11 Low birth weight by gravidity
Study or subgroup Mefloquine
Sulfadoxine-
pyrimethamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Primigravidae
Briand 2009 BEN 29/193 35/195 11.3 % 0.84 [ 0.53, 1.31 ]
Gonzalez 2014a BEN GAB MOZ TAN (1) 133/798 59/390 25.8 % 1.10 [ 0.83, 1.46 ]
Subtotal (95% CI) 991 585 37.1 % 1.02 [ 0.80, 1.30 ]
Total events: 162 (Mefloquine), 94 (Sulfadoxine-pyrimethamine)
Heterogeneity: Chi2 = 1.03, df = 1 (P = 0.31); I2 =3%
Test for overall effect: Z = 0.17 (P = 0.86)
2 Multigravidae
Briand 2009 BEN 30/542 37/535 12.1 % 0.80 [ 0.50, 1.28 ]
Gonzalez 2014a BEN GAB MOZ TAN 227/1980 118/1008 50.8 % 0.98 [ 0.79, 1.21 ]
Subtotal (95% CI) 2522 1543 62.9 % 0.94 [ 0.78, 1.14 ]
Total events: 257 (Mefloquine), 155 (Sulfadoxine-pyrimethamine)
Heterogeneity: Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
Total (95% CI) 3513 2128 100.0 % 0.97 [ 0.84, 1.13 ]
Total events: 419 (Mefloquine), 249 (Sulfadoxine-pyrimethamine)
Heterogeneity: Chi2 = 1.85, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 0.25, df = 1 (P = 0.62), I2 =0.0%
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(1) Low birth weight data by gravidity from Gonzalez et al were provided by the authors (unpublished results).
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Analysis 1.12. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 12 Prematurity.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 12 Prematurity
Study or subgroup Mefloquine
Sulfadoxine-
pyrimethamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Briand 2009 BEN 3/637 5/625 6.4 % 0.59 [ 0.14, 2.45 ]
Gonzalez 2014a BEN GAB MOZ TAN 118/2245 56/1133 93.6 % 1.06 [ 0.78, 1.45 ]
Total (95% CI) 2882 1758 100.0 % 1.03 [ 0.76, 1.40 ]
Total events: 121 (Mefloquine), 61 (Sulfadoxine-pyrimethamine)
Heterogeneity: Chi2 = 0.63, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 13 Malaria in first
year of life.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 13 Malaria in first year of life
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Gonzalez 2014a BEN GAB MOZ TAN -0.02623786 (0.08677885) 100.0 % 0.97 [ 0.82, 1.15 ]
Total (95% CI) 100.0 % 0.97 [ 0.82, 1.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 14 Hospital
admissions in first year of life.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 14 Hospital admissions in first year of life
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Gonzalez 2014a BEN GAB MOZ TAN -0.06969752 (0.11394933) 100.0 % 0.93 [ 0.75, 1.17 ]
Total (95% CI) 100.0 % 0.93 [ 0.75, 1.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 15 SAEs during
pregnancy.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 15 SAEs during pregnancy
Study or subgroup Mefloquine
Sulfadoxine-
pyrimethamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gonzalez 2014a BEN GAB MOZ TAN 275/3113 140/1561 100.0 % 0.98 [ 0.81, 1.20 ]
Total (95% CI) 3113 1561 100.0 % 0.98 [ 0.81, 1.20 ]
Total events: 275 (Mefloquine), 140 (Sulfadoxine-pyrimethamine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 16 Stillbirths and
abortions.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 16 Stillbirths and abortions
Study or subgroup Mefloquine
Sulfadoxine-
pyrimethamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Briand 2009 BEN 25/781 16/764 17.8 % 1.53 [ 0.82, 2.84 ]
Gonzalez 2014a BEN GAB MOZ TAN 126/3113 56/1561 82.2 % 1.13 [ 0.83, 1.54 ]
Total (95% CI) 3894 2325 100.0 % 1.20 [ 0.91, 1.58 ]
Total events: 151 (Mefloquine), 72 (Sulfadoxine-pyrimethamine)
Heterogeneity: Chi2 = 0.74, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 17 Congenital
malformations.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 17 Congenital malformations
Study or subgroup Mefloquine
Sulfadoxine-
pyrimethamine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Briand 2009 BEN 8/780 4/765 31.3 % 1.96 [ 0.59, 6.49 ]
Gonzalez 2014a BEN GAB MOZ TAN 25/2913 15/1473 68.7 % 0.84 [ 0.45, 1.59 ]
Total (95% CI) 3693 2238 100.0 % 1.10 [ 0.51, 2.37 ]
Total events: 33 (Mefloquine), 19 (Sulfadoxine-pyrimethamine)
Heterogeneity: Tau2 = 0.12; Chi2 = 1.50, df = 1 (P = 0.22); I2 =33%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours mefloquine Favours sulfadoxine-pyrimethamine
60Mefloquine for preventing malaria in pregnant women (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 1.18. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 18 Maternal
mortality.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 18 Maternal mortality
Study or subgroup Mefloquine
Sulfadoxine-
pyrimethamine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Briand 2009 BEN (1) 5/781 0/764 33.6 % 10.76 [ 0.60, 194.27 ]
Gonzalez 2014a BEN GAB MOZ TAN 9/3113 4/1561 66.4 % 1.13 [ 0.35, 3.66 ]
Total (95% CI) 3894 2325 100.0 % 2.41 [ 0.27, 21.23 ]
Total events: 14 (Mefloquine), 4 (Sulfadoxine-pyrimethamine)
Heterogeneity: Tau2 = 1.50; Chi2 = 2.18, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
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(1) Denominators based on stillbirths and abortions
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Analysis 1.19. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 19 Neonatal
mortality.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 19 Neonatal mortality
Study or subgroup Mefloquine
Sulfadoxine-
pyrimethamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Briand 2009 BEN (1) 11/738 12/722 22.7 % 0.90 [ 0.40, 2.02 ]
Gonzalez 2014a BEN GAB MOZ TAN 62/3113 31/1561 77.3 % 1.00 [ 0.65, 1.54 ]
Total (95% CI) 3851 2283 100.0 % 0.98 [ 0.67, 1.43 ]
Total events: 73 (Mefloquine), 43 (Sulfadoxine-pyrimethamine)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Not applicable
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(1) Data obtained by contacting the authors
Analysis 1.20. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 20 Infant mortality.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 20 Infant mortality
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Gonzalez 2014a BEN GAB MOZ TAN -0.00059042 (0.21374669) 100.0 % 1.00 [ 0.66, 1.52 ]
Total (95% CI) 100.0 % 1.00 [ 0.66, 1.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 1.21. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 21 AEs: vomiting.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 21 AEs: vomiting
Study or subgroup Mefloquine
Sulfadoxine-
pyrimethamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Briand 2009 BEN 437/802 93/799 41.2 % 4.68 [ 3.83, 5.72 ]
Gonzalez 2014a BEN GAB MOZ TAN 962/3112 100/1559 58.8 % 4.82 [ 3.96, 5.87 ]
Total (95% CI) 3914 2358 100.0 % 4.76 [ 4.13, 5.49 ]
Total events: 1399 (Mefloquine), 193 (Sulfadoxine-pyrimethamine)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 21.47 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours mefloquine Favours sulfadoxine-pyrimethamine
Analysis 1.22. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 22 AEs:
fatigue/weakness.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 22 AEs: fatigue/weakness
Study or subgroup Mefloquine
Sulfadoxine-
pyrimethamine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Briand 2009 BEN 321/802 106/799 53.5 % 3.02 [ 2.48, 3.67 ]
Gonzalez 2014a BEN GAB MOZ TAN 211/3112 14/1559 46.5 % 7.55 [ 4.41, 12.92 ]
Total (95% CI) 3914 2358 100.0 % 4.62 [ 1.80, 11.85 ]
Total events: 532 (Mefloquine), 120 (Sulfadoxine-pyrimethamine)
Heterogeneity: Tau2 = 0.42; Chi2 = 10.88, df = 1 (P = 0.00097); I2 =91%
Test for overall effect: Z = 3.19 (P = 0.0014)
Test for subgroup differences: Not applicable
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Analysis 1.23. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 23 AEs: dizziness.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 23 AEs: dizziness
Study or subgroup Mefloquine
Sulfadoxine-
pyrimethamine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Briand 2009 BEN 403/802 107/799 49.4 % 3.75 [ 3.11, 4.53 ]
Gonzalez 2014a BEN GAB MOZ TAN 1080/3112 115/1559 50.6 % 4.70 [ 3.92, 5.65 ]
Total (95% CI) 3914 2358 100.0 % 4.21 [ 3.36, 5.27 ]
Total events: 1483 (Mefloquine), 222 (Sulfadoxine-pyrimethamine)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.95, df = 1 (P = 0.09); I2 =66%
Test for overall effect: Z = 12.47 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.24. Comparison 1 Mefloquine versus sulfadoxine-pyrimethamine, Outcome 24 AEs: headache.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 1 Mefloquine versus sulfadoxine-pyrimethamine
Outcome: 24 AEs: headache
Study or subgroup Mefloquine
Sulfadoxine-
pyrimethamine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Briand 2009 BEN 9/802 23/799 43.6 % 0.39 [ 0.18, 0.84 ]
Gonzalez 2014a BEN GAB MOZ TAN 254/3112 115/1559 56.4 % 1.11 [ 0.90, 1.37 ]
Total (95% CI) 3914 2358 100.0 % 0.70 [ 0.25, 1.94 ]
Total events: 263 (Mefloquine), 138 (Sulfadoxine-pyrimethamine)
Heterogeneity: Tau2 = 0.46; Chi2 = 6.66, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 1 Clinical
malaria episodes during pregnancy.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 2 Mefloquine plus cotrimoxazole versus cotrimoxazole
Outcome: 1 Clinical malaria episodes during pregnancy
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Gonzalez 2014b KEN MOZ TAN -0.28 (0.43) 100.0 % 0.76 [ 0.33, 1.76 ]
Total (95% CI) 100.0 % 0.76 [ 0.33, 1.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 2 Maternal
peripheral parasitaemia at delivery (PCR).
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 2 Mefloquine plus cotrimoxazole versus cotrimoxazole
Outcome: 2 Maternal peripheral parasitaemia at delivery (PCR)
Study or subgroup Mefloquine+cotrimoxazoleCotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014a BEN 5/106 8/114 23.5 % 0.67 [ 0.23, 1.99 ]
Gonzalez 2014b KEN MOZ TAN 12/385 25/384 76.5 % 0.48 [ 0.24, 0.94 ]
Total (95% CI) 491 498 100.0 % 0.52 [ 0.30, 0.93 ]
Total events: 17 (Mefloquine+cotrimoxazole), 33 (Cotrimoxazole)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 2.22 (P = 0.027)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 3 Placental
malaria (blood smear).
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 2 Mefloquine plus cotrimoxazole versus cotrimoxazole
Outcome: 3 Placental malaria (blood smear)
Study or subgroup Mefloquine+cotrimoxazoleCotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014a BEN 0/117 1/116 4.3 % 0.33 [ 0.01, 8.03 ]
Gonzalez 2014b KEN MOZ TAN 17/449 34/462 95.7 % 0.51 [ 0.29, 0.91 ]
Total (95% CI) 566 578 100.0 % 0.51 [ 0.29, 0.89 ]
Total events: 17 (Mefloquine+cotrimoxazole), 35 (Cotrimoxazole)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 2.39 (P = 0.017)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours mefloquine+cotrimoxazole Favours cotrimoxazole
66Mefloquine for preventing malaria in pregnant women (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 2.4. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 4 Placental
malaria (PCR).
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 2 Mefloquine plus cotrimoxazole versus cotrimoxazole
Outcome: 4 Placental malaria (PCR)
Study or subgroup Mefloquine+cotrimoxazoleCotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014a BEN 0/105 5/103 16.4 % 0.09 [ 0.00, 1.59 ]
Gonzalez 2014b KEN MOZ TAN 9/388 28/381 83.6 % 0.32 [ 0.15, 0.66 ]
Total (95% CI) 493 484 100.0 % 0.28 [ 0.14, 0.57 ]
Total events: 9 (Mefloquine+cotrimoxazole), 33 (Cotrimoxazole)
Heterogeneity: Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 3.53 (P = 0.00041)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 5 Mean
haemoglobin at delivery.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 2 Mefloquine plus cotrimoxazole versus cotrimoxazole
Outcome: 5 Mean haemoglobin at delivery
Study or subgroup Mefloquine+cotrimoxazole Cotrimoxazole
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Denoeud-Ndam 2014a BEN 96 11.1 (1.4) 108 10.8 (1.5) 43.1 % 0.30 [ -0.10, 0.70 ]
Gonzalez 2014b KEN MOZ TAN 479 11.2 (2.1) 484 11.3 (2.2) 56.9 % -0.10 [ -0.37, 0.17 ]
Total (95% CI) 575 592 100.0 % 0.07 [ -0.32, 0.46 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 2.65, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 6 Maternal
anaemia at delivery (< 9.5 g/dL).
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 2 Mefloquine plus cotrimoxazole versus cotrimoxazole
Outcome: 6 Maternal anaemia at delivery (< 9.5 g/dL)
Study or subgroup Mefloquine+cotrimoxazoleCotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014a BEN 12/96 20/108 17.7 % 0.68 [ 0.35, 1.31 ]
Gonzalez 2014b KEN MOZ TAN (1) 87/495 88/498 82.3 % 0.99 [ 0.76, 1.30 ]
Total (95% CI) 591 606 100.0 % 0.94 [ 0.73, 1.20 ]
Total events: 99 (Mefloquine+cotrimoxazole), 108 (Cotrimoxazole)
Heterogeneity: Chi2 = 1.13, df = 1 (P = 0.29); I2 =12%
Test for overall effect: Z = 0.50 (P = 0.61)
Test for subgroup differences: Not applicable
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(1) Unpublished data. These were obtained by contacting the authors. In the original paper anaemia was defined as haemoglobin<11g/dl..
Analysis 2.7. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 7 Maternal
severe anaemia at delivery.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 2 Mefloquine plus cotrimoxazole versus cotrimoxazole
Outcome: 7 Maternal severe anaemia at delivery
Study or subgroup Mefloquine+cotrimoxazoleCotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014a BEN 0/96 0/108 Not estimable
Gonzalez 2014b KEN MOZ TAN 11/479 12/484 100.0 % 0.93 [ 0.41, 2.08 ]
Total (95% CI) 575 592 100.0 % 0.93 [ 0.41, 2.08 ]
Total events: 11 (Mefloquine+cotrimoxazole), 12 (Cotrimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 8 Cord blood
parasitaemia.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 2 Mefloquine plus cotrimoxazole versus cotrimoxazole
Outcome: 8 Cord blood parasitaemia
Study or subgroup Mefloquine+cotrimoxazoleCotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014a BEN (1) 0/117 0/116 Not estimable
Gonzalez 2014b KEN MOZ TAN 1/471 3/462 100.0 % 0.33 [ 0.03, 3.13 ]
Total (95% CI) 588 578 100.0 % 0.33 [ 0.03, 3.13 ]
Total events: 1 (Mefloquine+cotrimoxazole), 3 (Cotrimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
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(1) Denominators for this outcome were assumed based on the flow diagram.
Analysis 2.9. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 9 Mean birth
weight.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 2 Mefloquine plus cotrimoxazole versus cotrimoxazole
Outcome: 9 Mean birth weight
Study or subgroup Mefloquine+cotrimoxazole Cotrimoxazole
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Denoeud-Ndam 2014a BEN 119 2856 (454) 126 2889 (478) 27.5 % -33.00 [ -149.70, 83.70 ]
Gonzalez 2014b KEN MOZ TAN 489 3036.3 (570.6) 486 3059.3 (575.5) 72.5 % -23.00 [ -94.94, 48.94 ]
Total (95% CI) 608 612 100.0 % -25.75 [ -86.99, 35.49 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 10 Low birth
weight.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 2 Mefloquine plus cotrimoxazole versus cotrimoxazole
Outcome: 10 Low birth weight
Study or subgroup Mefloquine+cotrimoxazoleCotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014a BEN 24/119 26/126 35.4 % 0.98 [ 0.60, 1.60 ]
Gonzalez 2014b KEN MOZ TAN 61/489 46/486 64.6 % 1.32 [ 0.92, 1.89 ]
Total (95% CI) 608 612 100.0 % 1.20 [ 0.89, 1.60 ]
Total events: 85 (Mefloquine+cotrimoxazole), 72 (Cotrimoxazole)
Heterogeneity: Chi2 = 0.92, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 2.11. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 11
Prematurity.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 2 Mefloquine plus cotrimoxazole versus cotrimoxazole
Outcome: 11 Prematurity
Study or subgroup Mefloquine+cotrimoxazoleCotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Denoeud-Ndam 2014a BEN 16/125 20/130 59.9 % 0.83 [ 0.45, 1.53 ]
Gonzalez 2014b KEN MOZ TAN 14/284 9/285 40.1 % 1.56 [ 0.69, 3.55 ]
Total (95% CI) 409 415 100.0 % 1.07 [ 0.58, 1.96 ]
Total events: 30 (Mefloquine+cotrimoxazole), 29 (Cotrimoxazole)
Heterogeneity: Tau2 = 0.06; Chi2 = 1.46, df = 1 (P = 0.23); I2 =32%
Test for overall effect: Z = 0.22 (P = 0.82)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours mefloquine+cotrimoxazole Favours cotrimoxazole
Analysis 2.12. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 12 SAEs
during pregnancy.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 2 Mefloquine plus cotrimoxazole versus cotrimoxazole
Outcome: 12 SAEs during pregnancy
Study or subgroup Mefloquine+cotrimoxazoleCotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014a BEN 9/146 10/146 12.0 % 0.90 [ 0.38, 2.15 ]
Gonzalez 2014b KEN MOZ TAN 48/523 74/532 88.0 % 0.66 [ 0.47, 0.93 ]
Total (95% CI) 669 678 100.0 % 0.69 [ 0.50, 0.95 ]
Total events: 57 (Mefloquine+cotrimoxazole), 84 (Cotrimoxazole)
Heterogeneity: Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 2.30 (P = 0.022)
Test for subgroup differences: Not applicable
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Analysis 2.13. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 13
Spontaneous abortions and stillbirths.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 2 Mefloquine plus cotrimoxazole versus cotrimoxazole
Outcome: 13 Spontaneous abortions and stillbirths
Study or subgroup Mefloquine+cotrimoxazoleCotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Denoeud-Ndam 2014a BEN 12/146 6/146 42.5 % 2.00 [ 0.77, 5.19 ]
Gonzalez 2014b KEN MOZ TAN 20/523 28/532 57.5 % 0.73 [ 0.41, 1.27 ]
Total (95% CI) 669 678 100.0 % 1.12 [ 0.42, 2.98 ]
Total events: 32 (Mefloquine+cotrimoxazole), 34 (Cotrimoxazole)
Heterogeneity: Tau2 = 0.35; Chi2 = 3.22, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 2.14. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 14 Congenital
malformations.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 2 Mefloquine plus cotrimoxazole versus cotrimoxazole
Outcome: 14 Congenital malformations
Study or subgroup Mefloquine+cotrimoxazoleCotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014a BEN 1/146 2/146 20.2 % 0.50 [ 0.05, 5.45 ]
Gonzalez 2014b KEN MOZ TAN 5/505 8/515 79.8 % 0.64 [ 0.21, 1.94 ]
Total (95% CI) 651 661 100.0 % 0.61 [ 0.22, 1.67 ]
Total events: 6 (Mefloquine+cotrimoxazole), 10 (Cotrimoxazole)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 2.15. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 15 Maternal
mortality.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 2 Mefloquine plus cotrimoxazole versus cotrimoxazole
Outcome: 15 Maternal mortality
Study or subgroup Mefloquine+cotrimoxazoleCotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014a BEN 1/146 2/146 33.5 % 0.50 [ 0.05, 5.45 ]
Gonzalez 2014b KEN MOZ TAN 2/523 4/532 66.5 % 0.51 [ 0.09, 2.76 ]
Total (95% CI) 669 678 100.0 % 0.51 [ 0.13, 2.01 ]
Total events: 3 (Mefloquine+cotrimoxazole), 6 (Cotrimoxazole)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 2.16. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 16 Neonatal
mortality.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 2 Mefloquine plus cotrimoxazole versus cotrimoxazole
Outcome: 16 Neonatal mortality
Study or subgroup Mefloquine+cotrimoxazoleCotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014a BEN 4/129 3/130 23.1 % 1.34 [ 0.31, 5.88 ]
Gonzalez 2014b KEN MOZ TAN 13/488 10/492 76.9 % 1.31 [ 0.58, 2.96 ]
Total (95% CI) 617 622 100.0 % 1.32 [ 0.65, 2.69 ]
Total events: 17 (Mefloquine+cotrimoxazole), 13 (Cotrimoxazole)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 2.17. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 17 Mother-to-
child transmission HIV.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 2 Mefloquine plus cotrimoxazole versus cotrimoxazole
Outcome: 17 Mother-to-child transmission HIV
Study or subgroup Mefloquine+cotrimoxazoleCotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014a BEN 1/80 1/84 5.0 % 1.05 [ 0.07, 16.50 ]
Gonzalez 2014b KEN MOZ TAN 36/420 19/435 95.0 % 1.96 [ 1.14, 3.37 ]
Total (95% CI) 500 519 100.0 % 1.92 [ 1.13, 3.25 ]
Total events: 37 (Mefloquine+cotrimoxazole), 20 (Cotrimoxazole)
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 2.41 (P = 0.016)
Test for subgroup differences: Not applicable
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Analysis 2.18. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 18 AEs:
vomiting.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 2 Mefloquine plus cotrimoxazole versus cotrimoxazole
Outcome: 18 AEs: vomiting
Study or subgroup Mefloquine+cotrimoxazoleCotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Denoeud-Ndam 2014a BEN 50/146 0/146 38.0 % 101.00 [ 6.29, 1621.68 ]
Gonzalez 2014b KEN MOZ TAN 125/523 16/532 62.0 % 7.95 [ 4.79, 13.18 ]
Total (95% CI) 669 678 100.0 % 20.88 [ 1.40, 311.66 ]
Total events: 175 (Mefloquine+cotrimoxazole), 16 (Cotrimoxazole)
Heterogeneity: Tau2 = 3.00; Chi2 = 3.90, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 2.20 (P = 0.028)
Test for subgroup differences: Not applicable
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Analysis 2.19. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 19 AEs:
fatigue/weakness.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 2 Mefloquine plus cotrimoxazole versus cotrimoxazole
Outcome: 19 AEs: fatigue/weakness
Study or subgroup Mefloquine+cotrimoxazoleCotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Denoeud-Ndam 2014a BEN 30/146 3/146 48.5 % 10.00 [ 3.12, 32.04 ]
Gonzalez 2014b KEN MOZ TAN (1) 11/523 12/532 51.5 % 0.93 [ 0.42, 2.09 ]
Total (95% CI) 669 678 100.0 % 2.95 [ 0.26, 32.93 ]
Total events: 41 (Mefloquine+cotrimoxazole), 15 (Cotrimoxazole)
Heterogeneity: Tau2 = 2.77; Chi2 = 11.60, df = 1 (P = 0.00066); I2 =91%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
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(1) Unpublished data. These data were obtained by contacting the authors.
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Analysis 2.20. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 20 AEs:
dizziness.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 2 Mefloquine plus cotrimoxazole versus cotrimoxazole
Outcome: 20 AEs: dizziness
Study or subgroup Mefloquine+cotrimoxazoleCotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Denoeud-Ndam 2014a BEN 52/146 0/146 43.3 % 105.00 [ 6.54, 1685.03 ]
Gonzalez 2014b KEN MOZ TAN 155/523 40/532 56.7 % 3.94 [ 2.85, 5.46 ]
Total (95% CI) 669 678 100.0 % 16.34 [ 0.39, 684.99 ]
Total events: 207 (Mefloquine+cotrimoxazole), 40 (Cotrimoxazole)
Heterogeneity: Tau2 = 6.38; Chi2 = 7.28, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 2.21. Comparison 2 Mefloquine plus cotrimoxazole versus cotrimoxazole, Outcome 21 AEs:
headache.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 2 Mefloquine plus cotrimoxazole versus cotrimoxazole
Outcome: 21 AEs: headache
Study or subgroup Mefloquine+cotrimoxazoleCotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Denoeud-Ndam 2014a BEN 1/146 4/146 17.7 % 0.25 [ 0.03, 2.21 ]
Gonzalez 2014b KEN MOZ TAN 38/523 40/532 82.3 % 0.97 [ 0.63, 1.48 ]
Total (95% CI) 669 678 100.0 % 0.76 [ 0.28, 2.10 ]
Total events: 39 (Mefloquine+cotrimoxazole), 44 (Cotrimoxazole)
Heterogeneity: Tau2 = 0.28; Chi2 = 1.43, df = 1 (P = 0.23); I2 =30%
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 1 Maternal peripheral
parasitaemia at delivery (PCR).
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 3 Mefloquine versus cotrimoxazole
Outcome: 1 Maternal peripheral parasitaemia at delivery (PCR)
Study or subgroup Mefloquine Cotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014b BEN 1/48 5/50 100.0 % 0.21 [ 0.03, 1.72 ]
Total (95% CI) 48 50 100.0 % 0.21 [ 0.03, 1.72 ]
Total events: 1 (Mefloquine), 5 (Cotrimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 2 Placental malaria (PCR).
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 3 Mefloquine versus cotrimoxazole
Outcome: 2 Placental malaria (PCR)
Study or subgroup Mefloquine Cotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014b BEN 2/45 3/49 100.0 % 0.73 [ 0.13, 4.15 ]
Total (95% CI) 45 49 100.0 % 0.73 [ 0.13, 4.15 ]
Total events: 2 (Mefloquine), 3 (Cotrimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 3 Placental malaria (blood smear).
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 3 Mefloquine versus cotrimoxazole
Outcome: 3 Placental malaria (blood smear)
Study or subgroup Mefloquine Cotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014b BEN 0/53 1/55 100.0 % 0.35 [ 0.01, 8.30 ]
Total (95% CI) 53 55 100.0 % 0.35 [ 0.01, 8.30 ]
Total events: 0 (Mefloquine), 1 (Cotrimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 4 Mean haemoglobin at delivery.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 3 Mefloquine versus cotrimoxazole
Outcome: 4 Mean haemoglobin at delivery
Study or subgroup Mefloquine Cotrimoxazole
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Denoeud-Ndam 2014b BEN 47 11.2 (1.4) 53 11.3 (1.5) 100.0 % -0.10 [ -0.67, 0.47 ]
Total (95% CI) 47 53 100.0 % -0.10 [ -0.67, 0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 5 Maternal anaemia at delivery (<
9.5 g/dL).
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 3 Mefloquine versus cotrimoxazole
Outcome: 5 Maternal anaemia at delivery (< 9.5 g/dL)
Study or subgroup Mefloquine Cotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014b BEN 4/47 5/53 100.0 % 0.90 [ 0.26, 3.16 ]
Total (95% CI) 47 53 100.0 % 0.90 [ 0.26, 3.16 ]
Total events: 4 (Mefloquine), 5 (Cotrimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 6 Mean birth weight.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 3 Mefloquine versus cotrimoxazole
Outcome: 6 Mean birth weight
Study or subgroup Mefloquine Cotrimoxazole
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Denoeud-Ndam 2014b BEN 56 2902 (421) 64 3004 (436) 100.0 % -102.00 [ -255.52, 51.52 ]
Total (95% CI) 56 64 100.0 % -102.00 [ -255.52, 51.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 7 Low birth weight.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 3 Mefloquine versus cotrimoxazole
Outcome: 7 Low birth weight
Study or subgroup Mefloquine Cotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014b BEN 8/56 6/64 100.0 % 1.52 [ 0.56, 4.13 ]
Total (95% CI) 56 64 100.0 % 1.52 [ 0.56, 4.13 ]
Total events: 8 (Mefloquine), 6 (Cotrimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 8 Prematurity.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 3 Mefloquine versus cotrimoxazole
Outcome: 8 Prematurity
Study or subgroup Mefloquine Cotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014b BEN 5/60 5/65 100.0 % 1.08 [ 0.33, 3.56 ]
Total (95% CI) 60 65 100.0 % 1.08 [ 0.33, 3.56 ]
Total events: 5 (Mefloquine), 5 (Cotrimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
Test for subgroup differences: Not applicable
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Analysis 3.9. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 9 SAEs during pregnancy.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 3 Mefloquine versus cotrimoxazole
Outcome: 9 SAEs during pregnancy
Study or subgroup Mefloquine Cotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014b BEN 4/68 4/72 100.0 % 1.06 [ 0.28, 4.07 ]
Total (95% CI) 68 72 100.0 % 1.06 [ 0.28, 4.07 ]
Total events: 4 (Mefloquine), 4 (Cotrimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
Test for subgroup differences: Not applicable
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Analysis 3.10. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 10 Stillbirths.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 3 Mefloquine versus cotrimoxazole
Outcome: 10 Stillbirths
Study or subgroup Mefloquine Cotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014b BEN 4/67 1/72 100.0 % 4.30 [ 0.49, 37.49 ]
Total (95% CI) 67 72 100.0 % 4.30 [ 0.49, 37.49 ]
Total events: 4 (Mefloquine), 1 (Cotrimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 3.11. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 11 Spontaneous abortions.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 3 Mefloquine versus cotrimoxazole
Outcome: 11 Spontaneous abortions
Study or subgroup Mefloquine Cotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014b BEN 1/67 1/72 100.0 % 1.07 [ 0.07, 16.84 ]
Total (95% CI) 67 72 100.0 % 1.07 [ 0.07, 16.84 ]
Total events: 1 (Mefloquine), 1 (Cotrimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
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Analysis 3.12. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 12 Congenital malformations.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 3 Mefloquine versus cotrimoxazole
Outcome: 12 Congenital malformations
Study or subgroup Mefloquine Cotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014b BEN 2/67 2/72 100.0 % 1.07 [ 0.16, 7.41 ]
Total (95% CI) 67 72 100.0 % 1.07 [ 0.16, 7.41 ]
Total events: 2 (Mefloquine), 2 (Cotrimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
Test for subgroup differences: Not applicable
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Analysis 3.13. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 13 Maternal mortality.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 3 Mefloquine versus cotrimoxazole
Outcome: 13 Maternal mortality
Study or subgroup Mefloquine Cotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014b BEN 0/67 0/72 Not estimable
Total (95% CI) 67 72 Not estimable
Total events: 0 (Mefloquine), 0 (Cotrimoxazole)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 3.14. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 14 Neonatal mortality.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 3 Mefloquine versus cotrimoxazole
Outcome: 14 Neonatal mortality
Study or subgroup Mefloquine Cotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014b BEN 1/63 1/66 100.0 % 1.05 [ 0.07, 16.39 ]
Total (95% CI) 63 66 100.0 % 1.05 [ 0.07, 16.39 ]
Total events: 1 (Mefloquine), 1 (Cotrimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 3.15. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 15 Infant deaths after 7 days.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 3 Mefloquine versus cotrimoxazole
Outcome: 15 Infant deaths after 7 days
Study or subgroup Mefloquine Cotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014b BEN 2/63 1/66 100.0 % 2.10 [ 0.19, 22.54 ]
Total (95% CI) 63 66 100.0 % 2.10 [ 0.19, 22.54 ]
Total events: 2 (Mefloquine), 1 (Cotrimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
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Analysis 3.16. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 16 AEs: vomiting.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 3 Mefloquine versus cotrimoxazole
Outcome: 16 AEs: vomiting
Study or subgroup Mefloquine Cotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014b BEN 25/67 2/72 100.0 % 13.43 [ 3.31, 54.54 ]
Total (95% CI) 67 72 100.0 % 13.43 [ 3.31, 54.54 ]
Total events: 25 (Mefloquine), 2 (Cotrimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 3.63 (P = 0.00028)
Test for subgroup differences: Not applicable
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Analysis 3.17. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 17 AEs: fatigue/weakness.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 3 Mefloquine versus cotrimoxazole
Outcome: 17 AEs: fatigue/weakness
Study or subgroup Mefloquine Cotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014b BEN 13/67 2/72 100.0 % 6.99 [ 1.64, 29.81 ]
Total (95% CI) 67 72 100.0 % 6.99 [ 1.64, 29.81 ]
Total events: 13 (Mefloquine), 2 (Cotrimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 2.63 (P = 0.0087)
Test for subgroup differences: Not applicable
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Analysis 3.18. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 18 AEs: dizziness.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 3 Mefloquine versus cotrimoxazole
Outcome: 18 AEs: dizziness
Study or subgroup Mefloquine Cotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014b BEN 24/67 0/72 100.0 % 52.60 [ 3.26, 848.24 ]
Total (95% CI) 67 72 100.0 % 52.60 [ 3.26, 848.24 ]
Total events: 24 (Mefloquine), 0 (Cotrimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 2.79 (P = 0.0052)
Test for subgroup differences: Not applicable
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Analysis 3.19. Comparison 3 Mefloquine versus cotrimoxazole, Outcome 19 AEs: headache.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 3 Mefloquine versus cotrimoxazole
Outcome: 19 AEs: headache
Study or subgroup Mefloquine Cotrimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Denoeud-Ndam 2014b BEN 0/67 2/72 100.0 % 0.21 [ 0.01, 4.39 ]
Total (95% CI) 67 72 100.0 % 0.21 [ 0.01, 4.39 ]
Total events: 0 (Mefloquine), 2 (Cotrimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Mefloquine versus placebo, Outcome 1 Maternal peripheral parasitaemia
during pregnancy.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 4 Mefloquine versus placebo
Outcome: 1 Maternal peripheral parasitaemia during pregnancy
Study or subgroup Mefloquine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nosten 1994 THA 5/171 37/168 100.0 % 0.13 [ 0.05, 0.33 ]
Total (95% CI) 171 168 100.0 % 0.13 [ 0.05, 0.33 ]
Total events: 5 (Mefloquine), 37 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.35 (P = 0.000013)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Mefloquine versus placebo, Outcome 2 Placental malaria.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 4 Mefloquine versus placebo
Outcome: 2 Placental malaria
Study or subgroup Mefloquine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nosten 1994 THA 0/111 3/109 100.0 % 0.14 [ 0.01, 2.68 ]
Total (95% CI) 111 109 100.0 % 0.14 [ 0.01, 2.68 ]
Total events: 0 (Mefloquine), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Mefloquine versus placebo, Outcome 3 Mean birth weight.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 4 Mefloquine versus placebo
Outcome: 3 Mean birth weight
Study or subgroup Mefloquine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nosten 1994 THA (1) 146 2877 (433) 144 2957 (475) 100.0 % -80.00 [ -184.65, 24.65 ]
Total (95% CI) 146 144 100.0 % -80.00 [ -184.65, 24.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Not applicable
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(1) Denominators from live births
Analysis 4.4. Comparison 4 Mefloquine versus placebo, Outcome 4 Low birth weight.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 4 Mefloquine versus placebo
Outcome: 4 Low birth weight
Study or subgroup Mefloquine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nosten 1994 THA 24/146 17/144 100.0 % 1.39 [ 0.78, 2.48 ]
Total (95% CI) 146 144 100.0 % 1.39 [ 0.78, 2.48 ]
Total events: 24 (Mefloquine), 17 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 Mefloquine versus placebo, Outcome 5 Prematurity.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 4 Mefloquine versus placebo
Outcome: 5 Prematurity
Study or subgroup Mefloquine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nosten 1994 THA 4/102 8/97 100.0 % 0.48 [ 0.15, 1.53 ]
Total (95% CI) 102 97 100.0 % 0.48 [ 0.15, 1.53 ]
Total events: 4 (Mefloquine), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 4.6. Comparison 4 Mefloquine versus placebo, Outcome 6 Stillbirths.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 4 Mefloquine versus placebo
Outcome: 6 Stillbirths
Study or subgroup Mefloquine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nosten 1994 THA 11/159 4/152 100.0 % 2.63 [ 0.86, 8.08 ]
Total (95% CI) 159 152 100.0 % 2.63 [ 0.86, 8.08 ]
Total events: 11 (Mefloquine), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.091)
Test for subgroup differences: Not applicable
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Analysis 4.7. Comparison 4 Mefloquine versus placebo, Outcome 7 Spontaneous abortions.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 4 Mefloquine versus placebo
Outcome: 7 Spontaneous abortions
Study or subgroup Mefloquine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nosten 1994 THA 1/159 2/152 100.0 % 0.48 [ 0.04, 5.22 ]
Total (95% CI) 159 152 100.0 % 0.48 [ 0.04, 5.22 ]
Total events: 1 (Mefloquine), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
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Analysis 4.8. Comparison 4 Mefloquine versus placebo, Outcome 8 Congenital malformations.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 4 Mefloquine versus placebo
Outcome: 8 Congenital malformations
Study or subgroup Mefloquine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nosten 1994 THA 4/159 1/152 100.0 % 3.82 [ 0.43, 33.83 ]
Total (95% CI) 159 152 100.0 % 3.82 [ 0.43, 33.83 ]
Total events: 4 (Mefloquine), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 4.9. Comparison 4 Mefloquine versus placebo, Outcome 9 Maternal mortality.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 4 Mefloquine versus placebo
Outcome: 9 Maternal mortality
Study or subgroup Mefloquine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nosten 1994 THA (1) 1/171 0/168 100.0 % 2.95 [ 0.12, 71.85 ]
Total (95% CI) 171 168 100.0 % 2.95 [ 0.12, 71.85 ]
Total events: 1 (Mefloquine), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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(1) Denominators based on included participants
Analysis 4.10. Comparison 4 Mefloquine versus placebo, Outcome 10 Infant mortality.
Review: Mefloquine for preventing malaria in pregnant women
Comparison: 4 Mefloquine versus placebo
Outcome: 10 Infant mortality
Study or subgroup Mefloquine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nosten 1994 THA 25/144 24/144 100.0 % 1.04 [ 0.63, 1.74 ]
Total (95% CI) 144 144 100.0 % 1.04 [ 0.63, 1.74 ]
Total events: 25 (Mefloquine), 24 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.88)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Search strategies
Search set CIDG Specialized
Register
CENTRAL MEDLINE Embase LILACS
1 malaria Malaria ti, ab, MeSH Malaria ti, ab, MeSH Malaria ti, ab, Emtree malaria
2 Mefloquine OR Lar-
iam
Mefloquine ti, ab,
MeSH
Mefloquine ti, ab,
MeSH
Mefloquine ti, ab,
Emtree
Mefloquine
3 Pregnan* Lariam ti, ab Lariam ti, ab Lariam ti, ab Lariam
4 1 and 2 and 3 2 or 3 2 or 3 2 or 3 2 or 3
5 - 1 and 4 1 and 4 1 and 4 1 and 4
6 - Pregnan* ti, ab Pregnan* ti, ab Pregnan* ti, ab Pregnan$
7 - Pregnancy [Mesh] Pregnancy [Mesh] Pregnancy [Emtree] 5 and 6
8 - 6 or 7 6 or 7 6 or 7 -
9 - 5 and 8 5 and 8 5 and 8 -
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol, we indicated that for the safety evaluation of mefloquine in pregnancy, we would include studies that used mefloquine
to prevent malaria in pregnant women travelling tomalaria-endemic areas. However, evaluation of mefloquine safety compared with the
safety of other antimalarials was not possible because of the study design employed by retrieved studies. Consequently, no observational
studies met the inclusion criteria and only randomized controlled trials met the inclusion criteria of this review.
In the protocol, we listed neonatal morbidity in the first 28 days of life as an analysis outcome. Similarly, we listed mean haemoglobin
and maternal anaemia during pregnancy were as outcomes. However, the included trials did not report on these effects; consequently,
we were unable to perform the analyses.
One included trial reported an unexpected increased risk of mother-to-child transmission (MTCT) of HIV associated with IPTp-
mefloquine. Given the clinical relevance of this finding, we included the frequency of MTCT of HIV as an outcome of the analysis.
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